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Background: Newly diagnosed open-angle glaucoma (OAG) and ocular hypertension (OHT) are habitually
treated with intraocular pressure (IOP)-lowering eyedrops. Selective laser trabeculoplasty (SLT) is a safe
alternative to drops and is rarely used as first-line treatment.
Objectives: To compare health-related quality of life (HRQoL) in newly diagnosed, treatment-naive
patients with OAG or OHT, treated with two treatment pathways: topical IOP-lowering medication from
the outset (Medicine-1st) or primary SLT followed by topical medications as required (Laser-1st). We also
compared the clinical effectiveness and cost-effectiveness of the two pathways.
Design: A 36-month pragmatic, unmasked, multicentre randomised controlled trial.
Settings: Six collaborating specialist glaucoma clinics across the UK.
Participants: Newly diagnosed patients with OAG or OHT in one or both eyes who were aged ≥ 18 years
and able to provide informed consent and read and understand English. Patients needed to qualify for
treatment, be able to perform a reliable visual field (VF) test and have visual acuity of at least 6 out of 36
in the study eye. Patients with VF loss mean deviation worse than –12 dB in the better eye or –15 dB in the
worse eye were excluded. Patients were also excluded if they had congenital, early childhood or secondary
glaucoma or ocular comorbidities; if they had any previous ocular surgery except phacoemulsification,
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at least 1 year prior to recruitment or any active treatment for ophthalmic conditions; if they were pregnant;
or if they were unable to use topical medical therapy or had contraindications to SLT.
Interventions: SLT according to a predefined protocol compared with IOP-lowering eyedrops, as per
national guidelines.
Main outcome measures: The primary outcome was HRQoL at 3 years [as measured using the EuroQol-5
Dimensions, five-level version (EQ-5D-5L) questionnaire]. Secondary outcomes were cost and cost-effectiveness,
disease-specific HRQoL, clinical effectiveness and safety.
Results: Of the 718 patients enrolled, 356 were randomised to Laser-1st (initial SLT followed by routine
medical treatment) and 362 to Medicine-1st (routine medical treatment only). A total of 652 (91%) patients
returned the primary outcome questionnaire at 36 months. The EQ-5D-5L score was not significantly
different between the two arms [adjusted mean difference (Laser-1st – Medicine-1st) 0.01, 95% confidence
interval (CI) –0.01 to 0.03; p = 0.23] at 36 months. Over 36 months, the proportion of visits at which IOP
was within the target range was higher in the Laser-1st arm (93.0%, 95% CI 91.9% to 94.0%) than in the
Medicine-1st arm (91.3%, 95% CI 89.9% to 92.5%), with IOP-lowering glaucoma surgery required in
0 and 11 patients, respectively. There was a 97% probability of Laser-1st being more cost-effective than
Medicine-1st for the NHS, at a willingness to pay for a quality-adjusted life-year of £20,000, with a reduction
in ophthalmology costs of £458 per patient (95% of bootstrap iterations between –£585 and –£345).
Limitation: An unmasked design, although a limitation, was essential to capture any treatment effects on
patients’ perception. The EQ-5D-5L questionnaire is a generic tool used in multiple settings and may not
have been the most sensitive tool to investigate HRQoL.
Conclusions: Compared with medication, SLT provided a stable, drop-free IOP control to 74.2% of
patients for at least 3 years, with a reduced need for surgery, lower cost and comparable HRQoL. Based on
the evidence, SLT seems to be the most cost-effective first-line treatment option for OAG and OHT, also
providing better clinical outcomes.
Future work: Longitudinal research into the clinical efficacy of SLT as a first-line treatment will specify the
long-term differences of disease progression, treatment intensity and ocular surgery rates between the two
pathways.
Trial registration: Current Controlled Trials ISRCTN32038223.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 31.
See the NIHR Journals Library website for further project information.
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Plain English summary
G laucoma is an eye condition in which the optic nerve becomes damaged and, if left untreated, willlead to loss of vision. Ocular hypertension (OHT) is the medical name for high pressure in the eye that
increases the risk of getting glaucoma. Lowering the eye pressure is the only known way to prevent
glaucoma from getting worse. Before this trial, the standard initial treatment of these conditions was the
prescription of eyedrops to lower the pressure in the eye. An alternative is a laser therapy that is known
to reduce the eye pressure. This study investigated if starting treatment of glaucoma or OHT with laser
therapy (using eyedrops later, if needed) affected the patients’ quality of life (QoL) more or less than
starting treatment with eyedrops alone. The study also investigated if initial treatment with laser and initial
treatment with eyedrops are equally good at controlling eye pressure and are equally safe and how much
they cost the NHS. Patients were randomly assigned to starting treatment with either laser or eyedrops
and the two groups were then compared.
The study found that for the first 3 years QoL was similar regardless of treatment. However, three-quarters
of patients initially treated with laser did not need any eyedrops to control their eye pressure for 3 years.
Patients initially treated with laser were less likely to require cataract surgery, and none needed any
glaucoma surgery in the first 3 years. In contrast, among those patients treated with eyedrops, glaucoma
surgery was required in 11 eyes (out of 622 eyes). Initial treatment with laser was cheaper than initial
treatment with eyedrops.
The results of this study suggest that laser is an efficient, safe and cheaper alternative to eyedrops, and
that three-quarters of the patients initially treated with laser do not need any eyedrops for the first 3 years
of treatment.
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Scientific summary
Background
Glaucoma is a group of conditions characterised by the progressive damage of the optic nerve head and
loss of visual field (VF). It is a leading cause of visual morbidity in the UK, causing falls, road traffic accidents,
loss of independence in the elderly and a reduction in quality of life (QoL). Ocular hypertension (OHT), a
state of raised intraocular pressure (IOP) in otherwise healthy eyes, is a risk factor for developing glaucoma
and often requires treatment. The only known treatment for glaucoma and OHT is lowering the IOP; this
has traditionally been done with IOP-lowering eyedrops when patients are treated for the first time.
Glaucoma monitoring and treatment take up a major proportion of hospital eye service outpatient
appointments, with > 1 million glaucoma-related hospital eye service visits annually. Glaucoma treatment
incurs significant costs to both the NHS and the patients; in 2012 alone, > 8 million glaucoma treatment-
related items were dispensed in the community, costing > £105M. In addition, annual increases in the
items prescribed and their cost have been reported for more than a decade.
The traditional first-line treatment for glaucoma and OHT, IOP-lowering eyedrops, has numerous side
effects both topical and systemic. These range from mild to severe, take up a significant proportion of
outpatient visits and may affect the success of further glaucoma surgery. Glaucoma and its treatment have
been shown to have a significant negative impact on patients’ QoL as a result of impairments in visual
function, as well as the side effects of treatment.
An alternative to reducing IOP is selective laser trabeculoplasty (SLT), a quick and painless outpatient
procedure. Until now this has principally been used not as a first-line treatment but as a last resort before
intraocular surgery. However, this is because earlier forms of laser trabeculoplasty had a relatively low
safety margin and repeatability; SLT is better than earlier types of laser trabeculoplasty in both respects.
Selective laser trabeculoplasty has the potential of providing IOP control for glaucoma and OHT patients
without the need for topical medical treatment (eyedrops) and this has implications for both NHS expenditure
and the patients’ QoL. Additionally, the use of SLT from the outset of patients’ treatment may offer clinical
benefits in the later management of the disease.
Objective
To investigate if lowering IOP with SLT as a first-line treatment for patients with newly diagnosed OHT
or open-angle glaucoma (OAG) (Laser-1st) leads to a better health-related quality of life (HRQoL) than
first-line treatment with IOP-lowering eyedrops (Medicine-1st), and whether or not this is associated with
reduced costs, better clinical outcomes and improved tolerability of treatment.
Objectives
Primary objective
To determine if, in a pragmatic study that mirrors the realities of clinical decision-making, a Laser-1st (initial
SLT followed by routine medical treatment) pathway delivers a better HRQoL at 3 years than a Medicine-1st
(routine medical treatment only) pathway, in the management of patients with OAG or OHT.
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Secondary objectives
To determine whether or not a Laser-1st treatment pathway:
l costs less than the conventional treatment pathway of Medicine-1st
l achieves the desired level of IOP with less intensive treatment over the course of the study
l leads to equivalent levels of visual function after 3 years
l is better tolerated by patients.
Methods
We designed a pragmatic randomised control trial, with participants unmasked to treatment allocation,
across six UK NHS sites, to compare initial SLT followed by routine medical treatment (Laser-1st) with
routine medical treatment only (Medicine-1st).
Patients were adults, newly diagnosed with OAG or OHT, with no other ocular pathology and were
randomised in a 1 : 1 ratio to receive either SLT (Laser-1st) or medical therapy (Medicine-1st). Patients were
monitored for 3 years and received care in accordance with standard clinical practice.
Eyes were stratified into predefined categories of disease severity and were treated to achieve an eye-specific
target IOP generated by a decision support software (DSS), based on published research and internationally
recognised guidelines. SLT was performed in accordance with a strict protocol to standardise energy levels
and the number of shots. Medical treatment was conducted and escalated in accordance with guidelines
from the National Institute for Health and Care Excellence. Patient care, as well as monitoring intervals
and treatment escalations, was guided by the DSS. All DSS suggestions could be overruled by the treating
specialist consultant ophthalmologist if this was deemed to be to the patients’ benefit. In such cases the
consultant was required to record a detailed explanation for the decision. All measurements influencing
treatment escalation decisions (VF, Heidelberg retinal tomography and IOP) were made by masked observers.
Patients were sent a series of questionnaires investigating HRQoL, health-care resource use and
concordance at 6-month intervals [EuroQol-5 Dimensions, five-level version (EQ-5D-5L), Glaucoma Utility
Index (GUI), Glaucoma Symptom Scale (GSS), Glaucoma Quality of Life-15 (GQL-15), a modified Client
Service Receipt Inventory and two questions regarding concordance].
Statistical analysis
The primary outcome was analysed using linear regression with terms for randomisation arm, baseline
EQ-5D-5L, stratification factors (diagnosis and centre), baseline IOP and number of eyes affected at baseline.
The unit of analysis was the patient. If both of a patient’s eyes were included, baseline severity and IOP
were based on the worse eye, defined using VF mean deviation (MD) at baseline. EQ-5D-5L values missing
at 36 months were imputed using values at 30 months, if available. Sensitivity analyses were performed
to verify the results of the primary analysis. Mixed-effects models were used to analyse the EQ-5D-5L
measurements recorded at all time points to investigate possible changes in treatment effect over the
36 months (using interaction terms between randomisation arm and time) and to estimate the average
treatment effect over the 36-month follow-up period. The secondary outcomes were analysed using similar
regression methods. All analyses were performed on an intention-to-treat basis with participants analysed
according to the arm to which they were randomised.
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Economic evaluation
Quality-adjusted life-years (QALYs) were calculated over the course of the trial using the baseline and
6-monthly follow-up EQ-5D-5L questionnaires and calculating the area under the curve. Health-care
resource use cost was calculated using published sources. Eyedrops for OAG and OHT were costed based
on prescribed medications using the British National Formulary [Joint Formulary Committee. British National
Formulary (online). London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com
(accessed 15 July 2018)]. Cost-effectiveness acceptability curves were generated and the probability that
the intervention is cost-effective was investigated for a range of values of willingness to pay.
Results
Between October 2012 and October 2014 a total of 16,379 patients were assessed for eligibility (15,483
were excluded as a result of ineligibility). Of the 896 patients who were eligible, 718 (1235 eyes) were
recruited (80.1% participation rate), of whom 356 (613 eyes) were allocated to SLT (Laser-1st pathway)
and 362 (622 eyes) to medical treatment (Medicine-1st pathway).
The average age of the patients was 63.1 years (± 11.8 years) and more male patients than females were
recruited (55.3% males vs. 44.7% females). In total, 70% of all participants were white (black was the
second largest ethnic group; 20%). Thirty per cent of the patients reported a family history of glaucoma
affecting at least one first-degree relative.
A total of 301 patients (41.9%) had bilateral OAG, 161 patients (22.4%) had unilateral OAG (fellow eye
healthy), 93 patients (13.0%) had OAG in one eye and OHT in the other eye, 124 patients (17.3%) had
bilateral OHT and 39 patients (5.4%) had unilateral OHT (fellow eye healthy). A total of 555 patients
(77.2%) were classified as having OAG (if at least one eye had OAG) and 163 patients (22.7%) were
classified as having OHT; in 517 patients (72.0%) both eyes were eligible for the trial.
At baseline, the average EQ-5D-5L score was similar in the two treatment arms (Medicine-1st 0.92 ± 0.13;
Laser-1st 0.91 ± 0.13), as was the GUI score (Medicine-1st 0.89 ± 0.11; Laser-1st 0.89 ± 0.12) and the
GQL-15 score (Medicine-1st 18.7 ± 5.6; Laser-1st 18.9 ± 6.6). The average baseline GSS score was slightly
higher in the Medicine-1st arm than in the Laser-1st arm (Medicine-1st 83.3 ± 16.6; Laser-1st 81.4 ± 17.2).
Sixteen patients in the Laser-1st arm and nine patients in the Medicine-1st arm withdrew from the trial.
A total of 652 patients returned the primary outcome at 36 months, yielding a 91% return rate. At
36 months the Laser-1st arm had an average EQ-5D-5L score of 0.90 [standard deviation (SD) 0.16],
compared with 0.89 (SD 0.18) in the Medicine-1st arm [adjusted mean difference (Laser-1st –Medicine-1st)
0.01, 95% confidence interval (CI) –0.01 to 0.03; p = 0.23]. Taking into account the outcome data from all
time points across 36 months, the two treatment arms had similar EQ-5D-5L scores at 36 months (adjusted
mean difference 0.02, 95% CI –0.00 to 0.03).
The Laser-1st arm scored an average of 0.89 (SD 0.13) on the GUI, compared with 0.89 (SD 0.13) for the
Medicine-1st arm (adjusted mean difference 0.007, 95% CI –0.010 to 0.025). The Laser-1st arm had a
mean GSS score of 83.3 (SD 17.3) at 36 months, compared with 83.1 (SD 17.7) for the Medicine-1st arm
(adjusted mean difference 1.595, 95% CI –0.797 to 3.988). The mean GQL-15 scores at 36 months were
similar in the two arms (19.8 for Laser-1st and 19.8 Medicine-1st, adjusted mean difference –0.368,
95% CI –0.605 to 1.341).
At 36 months, 536 eyes (87.7%) of 314 patients in the Laser-1st arm and 536 eyes (86.2%) of 306 patients
in the Medicine-1st arm were available for analysis of clinical outcomes. The two treatment arms had
comparable end-point visual acuity [0.08 (SD 0.17) vs. 0.07 (SD 0.18) log of the minimum angle of resolution,
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Medicine-1st and Laser-1st, respectively)], IOP [16.3 (SD 3.9) vs. 16.6 (SD 3.6) mmHg, Medicine-1st and
Laser-1st, respectively] and VF MD [–3.2 dB for both arms (SD 3.8 dB Medicine-1st; SD 3.9 dB Laser-1st)].
Overall, 95% of the eyes treated with Laser-1st (n = 509) were at target IOP at 36 months, which was
achieved without medication for 78.2% of the eyes (n = 419), corresponding to 74.2% (n = 233, 95% CI
69.3% to 78.6%) of the patients. Of the eyes that received Medicine-1st, 93.1% (n = 499) were at target
IOP at 36 months; 64.6% (n = 346) were using a single medication. During the 36 months of the trial,
target IOP was achieved at 93% of visits in the Laser-1st arm, compared with 91.3% of visits in the
Medicine-1st arm. The number of treatment escalations was higher in the Medicine-1st arm than in in the
Laser-1st arm (348 vs. 299), as was the number of eyes showing disease deterioration (36 vs. 23); 11 eyes
in the Medicine-1st arm (1.8%) required IOP-lowering surgery (trabeculectomy), compared with none in
the Laser-1st arm. Twenty-five cataract extractions were carried out in the Medicine-1st arm and 13 in the
Laser-1st arm.
There were no sight-threatening complications of SLT. The IOP rose > 5 mmHg compared with baseline IOP
in six eyes of six patients who received SLT, but only one eye required treatment. Patients in the Medicine-
1st arm reported more ophthalmic eyedrop-related adverse events (AEs) (150 aesthetic side effects and
ocular allergic reactions were reported by 73 patients) than those in the Laser-1st arm (30 equivalent
events were reported by 20 patients). Transient AEs were reported by 34.4% (n = 122) of the patients in
the Laser-1st arm as a result of the SLT application. AEs during the SLT procedure were reported for 14
patients. Systemic AEs were similar in the two treatment arms. Eyedrop-related systemic AEs were reported
more often and by more patients in the Medicine-1st arm than in the Laser-1st arm [148 events reported
by 52 patients (14.4%) vs. 87 events reported by 23 patients (6.5%)]. Serious AEs were overall similar in
both arms: 95 in the Medicine-1st arm, affecting 68 patients, and 107 in the Laser-1st arm, affecting 64
patients.
Laser-1st dominated Medicine-1st in that it resulted in a greater QALY gain at a lower cost (although the
difference was not significant; p = 0.286). Laser-1st treatment cost £458 less than Medicine-1st, with
95% of bootstrap iterations falling between –£585 and –£345 (for specialist eye-related costs), and had a
mean incremental QALY gain of 0.011, with 95% bootstrap iterations falling between –0.024 and 0.050.
Over 36 months, discounted and adjusted, at willingness to pay for a QALY of £20,000 and £30,000,
the probability that Laser-1st is more cost-effective than Medicine-1st when only ophthalmology costs are
included is 97% and 93%, respectively. When community- and non-eye-related costs are added, there is a
68% chance that Laser-1st is more cost-effective, at willingness-to-pay levels of both £20,000 and £30,000.
Conclusions
This study shows that patients newly diagnosed with glaucoma or OHT can be safely treated with SLT
and achieve predominantly eyedrop-free IOP control over at least 3 years, with less intense treatment,
fewer AEs and a reduced need for glaucoma and cataract surgery, than patients treated with IOP-lowering
eyedrops. This can be achieved at a lower cost per QALY than standard medical therapy alone and with
a similar effect on generic HRQoL as assessed by the EQ-5D-5L. Primary SLT is a cost-effective alternative
to eyedrops that can be offered to patients with OAG or OHT who need IOP-lowering treatment.
Implications for health care
The findings of this trial have the potential to change glaucoma and OHT treatment worldwide. An eyedrop-
free IOP control may be a desired form of treatment for many patients and clinicians, while also providing
a cost-effective alternative to eyedrops. The results of this study may also have important implications for
resource-poor health-care settings where access to medication is a major barrier to glaucoma treatment
and/or where glaucoma prevalence is high.
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Despite the promising results with regard to the safety of the SLT procedure and the eyedrop-free IOP
control that SLT offers, clinicians need to consider the perceived necessity of monitoring visits by the
patient (patients may not always comprehend the necessity of frequent monitoring) in the absence of daily
medication. Patients need to understand the importance of attending follow-up visits and the lifelong need
for monitoring. SLT should not be perceived as a one-off glaucoma or OHT treatment and this needs to be
communicated clearly to patients.
Recommendations for research
l Longitudinal research into the clinical efficacy of SLT as a first-line treatment, with particular focus on
disease progression and ocular surgery rates.
l Longitudinal research into the effect of SLT on subsequent medicine-taking behaviour.
l Longitudinal HRQoL in OAG and OHT in particular (where data are lacking) to understand the impact of
medical treatment on patients over a longer period of time, when more intense medical treatment
might become necessary.
Longer follow-up already under way (the Laser in Glaucoma And Ocular Hypertension extension trial) will
help us answer the majority of the above questions.
Trial registration
The trial is registered as ISRCTN32038223.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Primary open-angle glaucoma and ocular hypertension
Primary open-angle glaucoma (OAG) is a common, irreversible optic neuropathy affecting the vision of
predominantly older adults. It is strongly associated with elevated intraocular pressure (IOP), but may also
occur with IOP in the normal range. Glaucoma results in progressive visual field (VF) loss and is a leading
cause of blindness worldwide. In the UK, glaucoma affects over half a million individuals, with over
one-quarter of a million aged > 65 years.1 It is a leading cause of visual morbidity, accounting for 12% of
blind registrations.2 Glaucoma is a significant cause of falls, road traffic accidents3 and loss of independence
in the elderly (even in the case of mild asymptomatic disease),3,4 and can significantly reduce the quality of
life (QoL) of these patients.5–8
Ocular hypertension (OHT) is a state of raised IOP without optic nerve damage, which can progress to
OAG in some patients.9,10 Those with a higher IOP, lower central corneal thickness (CCT) and a family
history of OAG are more at risk of developing glaucoma.11 IOP is the only modifiable risk factor for the
development of OAG, the reduction of which is proven to slow down the progression of OAG or the
conversion of OHT to OAG.10,12–14 National Institute for Health and Care Excellence (NICE) guidelines
recommend that patients with OHT at high risk of developing OAG should be offered treatment.15
Current first-line treatment options
Medical therapy (eyedrops) is widely used and is currently the most commonly used first-line treatment
for mild to moderate disease,16 leading to approximately 1.2 million prescriptions per month in the UK.17
Medical treatment is usually lifelong; patients may need to instil multiple eyedrops, which can become
expensive, while also experiencing side effects that limit the acceptability of the treatment and impair
their QoL.18–21
Although the effectiveness of IOP-lowering eyedrops is irrefutable, they come with a number of aesthetic,
sight- and potentially life-threatening side effects: pain on instillation, conjunctival hyperaemia, elongation
and darkening of eyelashes, iris colour changes, periocular skin pigmentation, allergic reactions, accelerated
cataract formation, cystoid macular oedema, anterior uveitis and reactivation of herpes simplex keratitis,19,20
in addition to serious respiratory (e.g. airway obstruction) and cardiovascular side effects in some, falls and
increased mortality.22,23 These adverse effects influence the acceptability of eyedrops to patients, as well as
patients’ concordance with medical treatment plans and their QoL. Indeed, reported non-compliance rates
for medical treatment range from 24% to 80%, depending on definition.24–26 Approximately 22% of initial
treatment regimens need adjustment27 and up to 50% of patients discontinue their medication within
6 months of the initial consultation.24 Although patients with diagnosed glaucoma are more likely than
those with suspected glaucoma to adhere to therapy,24 side effects are likely to have a direct adverse
effect on patients diagnosed with OHT, in whom proper IOP control can reduce the incidence of OAG.28
Medical management of OAG and OHT requires regular monitoring and modification of therapy by
ophthalmologists, as well as multiple hospital visits for patients.29
Long-term use of topical IOP-lowering medication induces significant subclinical conjunctival inflammation
and conjunctival fibroblast activation by medications or preservatives,30–32 and has been shown to have a
negative impact on the success rates of subsequent surgical intervention33 (long-term eyedrop use is a
known powerful risk factor for later surgical failure).31,34
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Laser trabeculoplasty (an alternative treatment method) has been inconsistently performed in the UK; NICE
has identified a lack of evidence governing its use.17 The procedure involves a single, painless outpatient
application of laser to the trabecular meshwork using a contact lens. It is easy to deliver by clinicians
competent in gonioscopy and has a wide safety margin. Selective laser trabeculoplasty (SLT) uses bursts
of nanosecond pulses with a larger spot (400 microns) and lowers IOP by increasing the aqueous humour
outflow through the trabecular meshwork by causing increased macrophage activity and trabecular tissue
remodelling.35,36
The IOP-lowering effect of SLT is comparable with that of prostaglandin analogues,37,38 the current first-line
medical treatment recommended by NICE. SLT can delay and, in some cases, prevent the need for eyedrops.38
The effects are not permanent; however, SLT does not prejudice the effectiveness of later medical or surgical
treatments. Because minimal trabecular meshwork damage is caused, SLT has also been shown to have good
efficacy on repeat treatment.39–41
The use of SLT for lowering IOP has been inconsistent and has in the past often been reserved as a last
resort before surgery, possibly because of concerns arising from older forms of laser trabeculoplasty. Use of
SLT as a first-line treatment has the potential to offer patients an eyedrop-free window of several years,
remove the concerns about concordance with medication and reduce both hospital visits and side effects
compared with medical therapy.
Glaucoma filtration surgery is usually reserved for those who continue to lose vision despite other
treatments. It has a significant failure rate and may cause permanent ocular discomfort and, rarely, chronic
pain.42,43 A study comparing medical management (eyedrops) with surgery (trabeculectomy) as a first-line
treatment for advanced OAG is currently under way.44
Economic burden of treatment to the NHS
The treatment of OAG and OHT can incur significant costs to both the patient and the NHS. Direct
treatment costs in the UK were estimated at an equivalent of US$1337 per patient per year in 1999;45
up to 61% of these costs were for IOP-lowering medication.46 In 2012, > 8 million glaucoma treatment-
related items were dispensed in the community alone, costing > £105M, with increases in the number of
items dispensed and their cost reported annually.47 Both direct costs and indirect costs are higher for more
severe disease,48 suggesting that effective IOP control early in the course of the disease is likely to reduce
later costs, as well as improve vision-dependent health-related quality of life (HRQoL).
Extensive economic modelling of SLT has taken place in various health-care systems worldwide. In the
USA, the 5-year cumulative costs per patient were lower for SLT than for eyedrops and surgery, whereas
an Australian study found that every AU$1 spent on laser treatment resulted in a saving of AU$2.50
compared with initial medical therapy, with projections of increasing cost savings over time.49,50 The time
threshold at which bilateral SLT would become less costly than bilateral use of topical medication has
also been modelled.51 It was found that SLT became less costly than most brand-name medications within
1 year and less costly than generic latanoprost and generic timolol eyedrops after 13 and 40 months,
respectively. This is supported by a projected 6-year cost comparison of primary SLT with primary medical
therapy in OAG treatment in a Canadian health-care model;46 if primary SLT had to be repeated between
2 and 3 years, use of primary SLT over mono-, bi-, and tri-drug therapy produced a 6-year cumulative cost
saving of CA$580.52, CA$2042.54 and CA$3366.65 per patient, respectively. Similar findings have also
been published for the management of both mild and moderate glaucoma.52
Although the limited existing data are very difficult to apply to the UK population, the above data would
suggest annual savings to the NHS of £2.4M in direct treatment costs for new OAG patients alone from a
Laser-1st (initial SLT followed by routine medical treatment) paradigm. This rises to £16.8M per year if a
conservative 20% of new OHT/OAG referrals require treatment. Australian data give far higher predictions:
were SLT to be extended to previously diagnosed patients, as is common practice in the USA, cost savings
would be up to 20 times higher. Indirect cost savings (e.g. reduced visual loss) are, of course, greater still.
INTRODUCTION
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Use of selective laser trabeculoplasty as a first-line treatment for open-angle glaucoma/
ocular hypertension
Initial treatment with SLT potentially offers an ‘eyedrop-free window’ of several years, removes concerns
about concordance and possibly reduces the need for multiple eyedrops, even years later. Even when
insufficient as a sole therapy, SLT may reduce the intensity of subsequent medical treatment and possibly
the need for later surgery. A single outpatient treatment is likely to be more acceptable to patients than daily
self-administration of eyedrops, securing 100% concordance from those attending for treatment and
resulting in fewer hospital visits and fewer side effects than eyedrop therapy alone.
Although SLT is an existing technology, proven to lower IOP, neither HRQoL nor cost-effectiveness has been
compared with outcomes in patients who received eyedrops as a first-line treatment. A Laser-1st pathway
allows an eyedrop-free period and, possibly, lower intensity of treatment. This is likely to be associated with
greater HRQoL, improved patient acceptability and better treatment compliance, with fewer patient visits
resulting from treatment changes and fewer adverse events (AEs), at a much lower cost than treatment with
eyedrops.46,50,53
Uptake of SLT by surgeons in the UK has so far been limited because of past experiences with older laser
technology. SLT is delivered in an outpatient setting using topical anaesthesia and is quick and pain free.
It is simple and safe to deliver and has a wide safety margin and good repeatability. Widespread uptake
of SLT has the potential to substantially improve HRQoL for many patients and produce substantial cost
savings to the NHS (lower medication costs, reduced side effects, fewer hospital visits, lower surgery rates
and indirect savings from care costs for fewer visually impaired patients).
Rationale for research
Research recommendations by NICE17 and a Cochrane systematic review54 have identified the need for
robust randomised controlled trials investigating the efficacy and cost-effectiveness of SLT as a first-line
treatment for OAG and OHT.
Aims and objectives
Hypothesis
Our hypothesis is that, in patients with newly diagnosed OHT or OAG, primary treatment with SLT (Laser-1st)
leads to a better HRQoL than primary treatment with IOP-lowering eyedrops (Medicine-1st), and that this is
associated with reduced costs, better clinical outcomes and an improved tolerability of treatment.
Primary objective
To determine if, in a pragmatic study that mirrors the realities of clinical decision-making, a Laser-1st
pathway delivers a better HRQoL at 3 years than a Medicine-1st (routine medical treatment only) pathway,
in the management of patients with OAG and OHT.
Secondary objectives
To determine whether or not a Laser-1st treatment pathway:
l costs less than the conventional treatment pathway of Medicine-1st
l achieves the desired level of IOP with less intensive treatment over the course of the study
l leads to equivalent levels of visual function after 3 years
l is better tolerated by patients.
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Chapter 2 Methods
Trial design
The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial was designed to evaluate the difference in
HRQoL, cost and clinical efficacy between two first-line treatment arms for OAG and OHT. The LiGHT trial is
a multicentre, randomised clinical trial, unmasked to treatment allocation, with two treatment arms: initial
SLT followed by routine medical treatment (Laser-1st) and routine medical treatment only (Medicine-1st).55,56
Eligible patients were randomised in a 1 : 1 ratio to receive either SLT (Laser-1st) or medical therapy
(Medicine-1st) as the first-line treatment for OAG or OHT. All measurements influencing treatment escalation
decisions [VF, Heidelberg retinal tomography (HRT) and IOP] were made by masked observers. Patients were
monitored for 3 years and monitoring intervals were guided by a defined protocol to avoid bias in clinical
decision-making. A clinical decision algorithm, attempting to capture the complexities of clinical practice,
defined triggers for escalation. This was a pragmatic trial aiming to mirror the ‘real-world’ patient experience
of treatment as closely as possible and seeking to capture the full effects of laser treatment.
Ethics approval and research governance
The study adhered to the tenets of the Declaration of Helsinki. Ethics approval was granted by the City
Road and Hampstead Research and Ethics Committee (former Moorfields and Whittington Research Ethics
Committee then East London and The City Research Ethics Committee 1, reference 12/LO/0940) on
20 June 2012. The LiGHT trial is registered as ISRCTN32038223 [the full protocol can be accessed at URL:
www.moorfields.nhs.uk/sites/default/files/LiGHT%20Trial%20Protocol%203.0%20-%2020-5-2015_3.pdf
(accessed 3 May 2019)].
Patient population
The LiGHT trial aimed to recruit patients with newly diagnosed OAG or OHT in one or both eyes from six
collaborating specialist glaucoma clinics at large ophthalmic centres in the UK (see Appendix 1).
Inclusion criteria
Parts of this text have been reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier
Ltd. This is an Open Access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
Patients were required to have newly diagnosed OAG or OHT in one or both eyes, which needed treatment.
Definitions of OAG and OHT, as well as criteria for initiating treatment, are shown in Appendix 2. The
following criteria were also specified:56
l A decision to treat had been made by a glaucoma specialist consultant ophthalmologist.
l Patients were aged > 18 years and were able to provide informed consent.
l Patients were able to complete QoL, disease-specific symptom and cost questionnaires in English
(physical help with completion and assistance with reading was permitted, as long as an interpreter was
not required).
l It was possible to perform a VF test in the study eye(s) with < 15% false positives.
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Exclusion criteria
Parts of this text have been reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier
Ltd. This is an Open Access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
Patients were not considered for the study if there was:56
l advanced glaucoma in the potentially eligible eye as determined by Early Manifest Glaucoma Trial
(EMGT I)59 criteria (77 VF loss mean deviation (MD) worse than –12 dB in the better eye or –15 dB in the
worse eye)
l secondary glaucoma (e.g. pigment dispersion syndrome, rubeosis, trauma, etc.) or any angle closure
l any contraindication to SLT (e.g. unable to sit at the laser-mounted slit-lamp, past history of or active
uveitis, neovascular glaucoma, inadequate visualisation of trabecular meshwork)
l an inability to use topical medical therapy because of, for example, physical infirmity and a lack of
carers able to administer daily eyedrops
l a previous treatment for OAG or OHT
l congenital or early childhood glaucoma
l a visually significant cataract in symptomatic patients who want to undergo cataract surgery
l any current, active treatment for another ophthalmic condition in the hospital eye service (this applied
to both eyes, even if one was not in the trial, as the fellow eye might affect the patient’s visit
frequency)
l any history of retinal ischaemia, macular oedema or diabetic retinopathy
l age-related macular degeneration with neovascularisation in either eye or geographic atrophy
l visual acuity (VA) worse than 6/36 in a study eye; non-progressive VA loss better than 6/36 owing to
any comorbidity was permitted provided that it did not affect the response to treatment or later surgical
choices and that it was not under active follow-up (e.g. an old, isolated retinal scar no longer under
review or amblyopia)
l any previous intraocular surgery, except uncomplicated phacoemulsification, at least 1 year before
recruitment (this applied to both eyes, even if one was not in the trial, as it could affect the required
treatment intensity and visit frequency for any glaucoma in the fellow eye)
l pregnancy at the time of recruitment or intention to become pregnant within the duration of the trial
l medical unsuitability for completion of the trial (e.g. suffering from a terminal illness or too unwell to be
able to attend hospital clinic visits)
l recent involvement in another interventional research study (within 3 months) of any topic.
Recruitment
Internal pilot study
We conducted a 9-month internal pilot at Moorfields Eye Hospital (MEH) (the central trial site and largest
recruiting site). This ensured that recruitment rates were adequate and that all procedures were in place,
before roll-out to other sites. Data collected included number of eligible patients approached, proportion
entering the trial and recruitment rates.
Recruitment strategy and identification of participants
Patients attending the hospital eye service for the first treatment of OAG/OHT were assessed for eligibility
before treatment and, if eligible, were informed of the study by the local trial co-ordinator (along with
written information). To maximise potential coverage of all eligible patients, a trial staff member was
available daily to attend clinics and counsel potential subjects. Local trial staff screened all new referrals
(by referral letter or electronic patient record) and identified those possibly eligible, with reminders for the
clinic staff. Regular education of clinical staff and clinic-wide information posters for staff and patients
raised awareness of the study and reminded clinicians of the opportunity for recruitment.56
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Recruitment process and informed consent
Eligible patients were approached and introduced to the aims, methods, anticipated benefits and potential
hazards of the study, and were eventually invited to participate by a member of the LiGHT team. Introducing
the patients to the study and inviting them to participate was done either by face-to-face discussions with the
trial team members or by the use of audiovisual material (video); the video conveyed the same information as
the face-to-face discussions with the trial team members, but was delivered by the chief investigator (video
content/script is shown in Appendix 3). The use of the video in the recruitment process maximised the time
efficiency of the recruiters, as often more than one patient had to be approached simultaneously.
After the invitation to participate, ample time was given to the patients to consider participation. Written
informed consent was obtained on a separate day, usually the day of the baseline assessment (see Baseline
assessment), by either the good clinical practice (GCP)-trained local trial ophthalmologist or the local trial
optometrist who had been delegated this duty by the chief investigator/principal investigator (PI) on the
delegation log. Consent was obtained with the support of extensive clearly written information (in English)
that had been reviewed and approved by our patient-led lay advisory group (LAG). Patients who had
difficulty in giving informed consent did not form part of this study. A copy of the signed informed consent
was given to the participant and the original signed form was retained at the study site.
If new safety information resulted in significant changes in the risk/benefit assessment, the consent form
was reviewed and updated if necessary. All patients, including those already being treated, were given any
new information, a copy of the revised form and reconsented to continue in the study.
Baseline assessment
At the baseline assessment, and after informed consent was provided, participants underwent VA testing,
slit-lamp examination, automated VF testing [Humphrey Field Analyser Mark II (Carl Zeiss Meditec, Dublin,
CA, USA) and the Swedish Interactive Threshold Algorithm standard 24-2 programme], HRT optic disc
imaging, IOP measurement, gonioscopy, CCT measurement and assessment of the optic discs, maculae
and fundi. The patients also completed the following baseline questionnaires: EuroQol-5 Dimensions,
five-level version (EQ-5D-5L),60 Glaucoma Utility Index (GUI),61 Glaucoma Symptom Scale (GSS),62 Glaucoma
Quality of Life-15 (GQL-15; a visual function, rather than quality-of-life measure)8 and a modified version of
the Client Service Receipt Inventory (CSRI) questionnaire.63
Randomisation and masking
Following the completion of all baseline assessments, eligible patients were randomised to one of two
treatment groups: SLT (Laser-1st) or topical medical therapy (Medicine-1st). Randomisation was undertaken
online on the same day by the clinical staff who obtained informed consent, using a web-based
randomisation service (Sealed Envelope, London, UK) and achieving full allocation concealment. Stratified
randomisation with random block sizes was used to randomise in a 1 : 1 ratio at the level of the patient,
with the stratification factors of diagnosis (OHT/OAG) and treatment centre. Following randomisation, the
details of the treatment and specific arrangements and instructions were communicated to the patients by
a member of the trial team. Owing to the pragmatic design of this trial, the patients and clinicians were
unmasked to the treatment arm; however, all clinical measurements (IOP, VF, HRT) were carried out by
masked observers and treatment decisions were masked by the use of a computerised evidence-based
decision support algorithm.56
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Treatment arm allocation
Laser-1st pathway
Selective laser trabeculoplasty was delivered to 360° of the trabecular meshwork with one 360° retreatment
used as the first escalation of treatment, if required. To ensure quality control of SLT delivery and to minimise
variation between surgeons, standardisation was achieved by a stringent protocol defining laser settings and
technique, including the range of acceptable powers (see Appendix 4). All treating clinicians were given
training before recruitment and had at least one laser treatment directly observed by the chief investigator.
After two SLT treatments, if further treatment escalation was required, the Laser-1st pathway patients
embarked on medical treatment and followed the Medicine-1st algorithms. Significant complications of
laser treatment, if they occurred (e.g. corneal oedema, intraocular haemorrhage, severe uveitis, IOP spike
> 15 mmHg, peripheral anterior synechiae), meant that a second treatment with SLT was contraindicated.
Other new medical conditions (such as a new history of uveitis or rubeosis) also precluded repeat SLT.56
Medicine-1st pathway
Medical treatment of glaucoma involves several distinct steps that require standardisation: choice of drugs,
number of agents permitted and rules for switching between or adding drugs. International best practice
guidelines advocate changing medication if the target is not reached, with the addition or switching of
medication (based on the magnitude of initial response).64–66 Surgery was offered once maximum treatment
intensity was reached; this varied between patients, but required definition to minimise inter-surgeon
variation (see Maximum medical treatment).
Choice of agent
No mainstream medications were prohibited, but medication classes for first-, second- or third-line
treatment were defined as per NICE1 and European Glaucoma Society guidance:67
l first line: prostaglandin analogue
l second line: beta-blocker (once in the morning or in a prostaglandin analogue combination)
l third or fourth line: topical carbonic anhydrase inhibitor or alpha-adrenoceptor agonist.
Systemic carbonic anhydrase inhibitors were permitted only as a temporising measure while awaiting
surgery and did not influence treatment escalation. Cholinergic agonists were not accepted as topical
medications for OAG.
Treatment changes
Treatment was escalated under the following circumstances:
l Strong evidence of progression (see Defining progression) irrespective of IOP.
l IOP above the target IOP (see Adding/switching medication) by > 4 mmHg68 at a single visit (irrespective
of evidence for progression).
l IOP above target by < 4 mmHg plus less strong evidence for progression (see Defining progression).
If the IOP was above target by less than the threshold with no evidence for progression, then the target
IOP was re-evaluated.
Adding/switching medication
The incremental escalation of the treatment protocol defined stepwise increases in treatment. Patients’
medications were switched if the pre- and post-treatment IOP difference was no greater than the
measurement error. If there was a greater reduction but the eye was still not at target, then the next
medication was added. The progression of glaucomatous optic neuropathy (GON) when at target IOP,
also triggered a stepwise increase in treatment and a lowering of the target.56
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Maximum medical treatment
Maximum medical treatment (MMT) is the most intensive combination of eyedrops a given individual can
reasonably, reliably and safely use. The MMT varies between patients depending on their comorbidities, side
effects and patient-specific concordance factors. Although there is variation in the attitudes of surgeons to
polypharmacy, it is widely accepted that additional medications result in a lower percentage reduction in
IOP. Evidence shows there are profound reductions in compliance with complex dosage schedules. NICE
guidance15 recommends offering surgery after only two drugs have failed to control IOP. In the LiGHT trial,
treatment with multiple different medications was limited and MMT was defined in terms of the maximum
number of drugs (three) and dosages per day (five drops). The MMT was often less owing to drug intolerance,
contraindications and patient factors.56
Disease stratification and initiation of treatment
The NICE-recommended thresholds were used for defining disease (OAG or OHT) for entry into the study,
as well as in initiating treatment (see Appendix 2).15 The patients’ clinical evaluation and test outcomes were
then entered into the clinical decision algorithm and a disease category and stage were determined. The
algorithm used severity criteria from the Canadian target IOP workshop,69 with central-field loss severity
criteria defined according to Mills et al.70 (Table 1). Severity stratification determined the follow-up
frequency.
Computerised decision algorithm
The follow-up and treatment escalation protocols were enabled by custom-written clinical decision support
software (DSS), which permitted real-time decision-making based on the analysis of multiple clinical measures,
including HRT optic disc analysis, VF assessment and IOP measurements. Predefined objective indicators of
either disc or field deterioration [change in mean neuroretinal rim area, as determined by HRT, or VF glaucoma
progression analysis (GPA)], or IOP above target all triggered earlier follow-up and/or increased treatment
intensity.
Setting individual target intraocular pressure
Once the decision to treat was made, a treatment target IOP (target) was set. The target was eye specific
and was objectively defined and adjusted by the computerised decision algorithm to avoid bias from
unmasked treating clinicians. The lowest permitted target was 8 mmHg for OAG and 18 mmHg for OHT.
TABLE 1 Severity criteria for setting a treatment target IOP from the Canadian target IOP workshop69 (with central
field criteria defined according to Mills et al.70)
Severity
Definition for treatment target IOP
Optic nerve VF MD Central (10°) scotoma on VF
OHT Healthy Any No GON-related VF loss
Mild OAG GON + > –6 dB + None
Moderate OAG GON + < –6 dB and > –12 dB or At least one central 5º point < 15 dB but none < 0 dB and
only one hemifield with a central point < 15 dB
Severe OAG GON + < –12 dB or Any central 5º point with sensitivity < 0 dB. Both hemifields
contain point(s) < 15 dB within 5º of fixation
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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Although CCT has an effect on IOP measurement and risk of progression, the true magnitude of this
interaction is unknown because of complex non-linear interactions between CCT, ‘true’ IOP and corneal
material properties; CCT was therefore not used in the algorithm for setting a target IOP.56 Myopia and
family history were also not included in this algorithm, as data on the effect size of these risk factors on
progression rates are weak.71 The target IOP was either an absolute reduction to below a specified level
or a percentage reduction from baseline, whichever was lower. The process of setting the IOP target is
illustrated in Figure 1. Greater reductions were required for greater disease severity as defined by Canadian
glaucoma study criteria.73
Setting the treatment target IOP
Recruitment
OHT
< 25 mmHg and
> 20% reduction
Randomisation and
initiation of treatment
Monitor and treatment
as required
POAG
aMild: < 21 mmHg and > 20% reduction
aModerate: < 18 mmHg and > 30% reduction
aSevere: < 15 mmHg and > 30% reduction
Failure to meet
target, without
progression
Increase target tolerance
Reduce target by 20% 
and intensify treatment
Intensive monitoring: 4/12 disc and VF
Progression of GON
(disc or field)
at IOP target
FIGURE 1 Process for target IOP setting. a, Disease stratification according to Mills et al.70 POAG, primary open-angle
glaucoma. Adapted by permission from BMJ Publishing Group Limited. The Laser in Glaucoma and Ocular Hypertension
(LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics, Konstantakopoulou E, Gazzard G,
Vickerstaff V, Jiang Y, Nathwani N, Hunter R, Ambler G, Bunce C, volume 102, pp. 599–603, 2018.72
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Failure to meet target intraocular pressure and target intraocular
pressure re-evaluation
Parts of this text have been reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier
Ltd. This is an Open Access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
Diurnal fluctuation and measurement error both lead to variation in measured IOP. Kotecha et al.68 have
shown that inter-visit variation may nonetheless be as much as ± 4 mmHg.68 To prevent an inappropriate
escalation to a more intensive treatment, it is therefore important to repeat measurements that deviate
only slightly from target. Criteria for failure to meet, and to reassess, target IOP follow those of the
Canadian glaucoma study,74 taking into account that inter-visit variation in IOP measurement may be as
much as ± 4 mmHg:
l If IOP in an eye was ≥ 2 mmHg but < 4 mmHg above target on two consecutive visits and showed
possible or definite progression, then the treatment was intensified and the target remained unchanged.
l If IOP in an eye was ≥ 2 mmHg and < 4 mmHg above target on two consecutive visits and showed no
progression (with a minimum of three post-baseline follow-up VF tests required to confirm progression,
as per EMGT I),59 then the target was adjusted upwards. In this case the target IOP was revised to the mean
of the previous three visits, during which progression did not occur. If VF testing had been carried out at
fewer than three follow-up visits, additional visits were required to confirm stability before the target
was relaxed.
l If IOP in an eye was ≥ 4 mmHg from target at any visit, then the eye was considered to have failed to
reach target and treatment intensity was increased to the next level (unless already at the maximum),
irrespective of any progression, unless the clinician identified poor concordance with treatment. In such
cases the target remained unchanged. In the presence of poor concordance and in the absence of
progression, additional measures to improve concordance before escalation of treatment were
permitted, as in usual clinical practice.
l If the IOP of an eye on MMT was ≥ 2 mmHg from target and showed definite progression, then
glaucoma drainage surgery was offered to the patient.
l If the IOP of an eye on MMT was ≥ 2 mmHg from target and showed possible progression, then the
follow-up frequency was increased until progression was either confirmed or ruled out.
l If the IOP of an eye on MMT was ≥ 2 mmHg from target but below maximum IOP (maximum IOP is
that above which surgery may be offered even without progression: OHT, 35 mmHg; mild glaucoma,
24 mmHg; moderate and severe glaucoma, 21 mmHg), and showed no progression (with at least three
follow-up VFs), then the target was adjusted (revised to the mean of the previous three visits) with an
increase in follow-up frequency. If VF testing had been carried out at fewer than three follow-up visits,
additional visits were required to confirm stability.
l A patient with an eye with IOP above the maximum IOP may have been offered surgery without
progression at the discretion of the treating surgeon.
l If there was progression and the IOP was at target, then the target IOP was reduced by 20% (according
to the Canadian glaucoma study protocol),74 with a lower limit of 8 mmHg, and treatment intensified
accordingly.
Failure to meet target can be a result of poor concordance as well as a lack of drug efficacy. As is normal
practice, compliance was discussed and patients were counselled at each visit, using validated ‘ask–tell–ask’
techniques.75–77 Patients were given standard written information from the International Glaucoma
Association, face-to-face instruction in eyedrop administration and the offer of further nurse-led support.
Where poor concordance was thought to be the contributing factor, education with written information and
repeated face-to-face instruction in eyedrop administration was given. If the decision was made to educate
rather than escalate a patient who was not at target, then the reason for an algorithm over-ride was recorded
(non-concordance) and the patient recalled after 8 weeks for a repeat IOP check visit.56
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Treatment escalation
To minimise bias for escalating treatment, standardised criteria for any additional intervention were used,
in accordance a protocol following international guidelines by the European Glaucoma Society,64 American
Academy of Ophthalmology Preferred Practice Pattern65 and the South East Asia Glaucoma Interest
Group.66 Treatment is escalated under the following circumstances:56
l Strong evidence of progression irrespective of IOP (see Defining progression).
l IOP above target by > 4 mmHg at a single visit (irrespective of evidence of progression).
l IOP above target by < 4 mmHg and less strong evidence of progression (see Defining progression). If the
IOP is above target by < 4 mmHg with no evidence of progression, then the treatment target IOP is
re-evaluated (see Failure to meet target intraocular pressure and target intraocular pressure re-evaluation).
The process for escalating treatment is shown in Figures 2 and 3.
More stringent criteria than those used for laser or medical treatment were applied before being referred
for surgery. This reflected the greater risk to a patient’s vision from surgical complications. Strong evidence
of progression and/or failure to meet target was usually required in all but the most severe disease.
However, extreme elevations of IOP could be an indication for surgery without progression, with lower
thresholds in more damaged eyes. Any patient in whom IOP was at or above the maximum was reviewed
(in person or remotely) by the PI, who decided whether or not surgery was indicated. In accordance with
the principle of patient-centred care, the decision to operate was always a collaboration between clinician
and patient. When an IOP-lowering surgical intervention was indicated, cataract surgery was permitted
(in the presence of cataract, i.e. not clear lens extraction) when this was the consultant’s usual practice.
IOP above target
≥ 2 mmHg
< 4 mmHg above
targeta
Meeting treatment target IOP (OHT)
Target revisedb
≥ 4 mmHg above
target
not MMT 
≥ 2 mmHg above
target
on MMT 
No
progression
Treatment
intensified and
target unchanged
Surgery
No
progression
Definite
progression
Increase VF
frequencyc
Possible or
definite
progression
Possible
progression
≥ 4 mmHg and 
< maximal IOP
on MMT 
≥ 35 mmHg
on MMT
FIGURE 2 Process for escalating treatment in OHT. a, On two consecutive visits; b, as per protocol; and c, until
progression confirmed/refuted. VF progression required three follow-up VF assessments. Maximal IOP, IOP above
which surgery was offered even without progression or 35mmHg for OHT. Adapted by permission from BMJ
Publishing Group Limited. The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised
controlled trial: baseline patient characteristics, Konstantakopoulou E, Gazzard G, Vickerstaff V, Jiang Y, Nathwani N,
Hunter R, Ambler G, Bunce C, volume 102, pp. 599–603, 2018.72
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Defining progression
Visual field progression
Worsening of VF loss was defined as ‘likely’ or ‘possible’ in the absence of any identifiable retinal or
neurological cause. The ‘minimum data set’ to determine VF progression was two reliable baseline VF
measurements followed by three follow-up VF tests. ‘Likely VF progression’ was defined as ≥ 3 points
on the Humphrey Visual Field (HVF) GPA software (Carl Zeiss Meditec, Dublin, CA, USA) at p < 0.05 for
change on three consecutive occasions. ‘Possible VF progression’ was ≥ 3 points on Humphrey Visual Field
GPA software at p < 0.05 for change on two consecutive occasions. VF series were independently assessed
for progression using the automated algorithm software at each visit. Any treatment escalation triggered
by worsening VF loss had to be agreed by a senior clinician after excluding retinal or neurological causes.56
Optic disc progression
Chauhan et al.78 showed that sequential HRT three-disc assessment performed as well as, or better than,
‘experts’ judging monoscopic photos. Simultaneous stereoscopic disc photography has been considered a
gold standard, but it is rarely available. Worsening of disc damage was defined as a rate of neuroretinal
rim loss exceeding 1% of baseline rim area per year on a minimum of five repeat HRT images. This slope
value was selected as approximately double that of age-related rim area loss and gave a similar specificity
to VF trend analyses.79
Open-angle glaucoma progression
Progression of glaucoma is defined as:
l Strong evidence: GPA ‘likely progression’ and/or HRT rim area > 1% per year (p < 0.001).
l Less strong evidence: GPA ‘possible progression’ and/or HRT rim area > 1% per year (p < 0.01).
IOP above target
≥ 2 mmHg
< 4 mmHg above
targeta
Meeting treatment target IOP (POAG)
Target revisedb
≥ 4 mmHg above
target
not MMT 
≥ 2 mmHg above
target
on MMT 
No
progression
Treatment
intensified and
target unchanged
Surgery
No
progression
Definite
progression
Increase VF
frequencyc
Possible or
definite
progression
Possible
progression
≥ 4 mmHg and 
< maximal IOP
on MMT 
> maximal IOP
on MMT
FIGURE 3 Process for escalating treatment in OAG. a, On two consecutive visits; b, as per protocol; and c, until
progression confirmed/refuted. VF progression required three follow-up VF assessments. Maximal IOP, IOP above
which surgery was offered even without progression or 35mmHg for OHT. Adapted by permission from BMJ
Publishing Group Limited. The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised
controlled trial: baseline patient characteristics, Konstantakopoulou E, Gazzard G, Vickerstaff V, Jiang Y, Nathwani N,
Hunter R, Ambler G, Bunce C, volume 102, pp. 599–603, 2018.72
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Algorithm over-ride
In the following cases the algorithm was over-ridden by the treating consultant if:
l Poor concordance was thought to be the contributing factor to failure to meet IOP target and was
followed by patient education and a recall 8 weeks after for an IOP check.
l It was felt that it was in the patient’s best interest to over-ride the algorithm’s decision to either revise
the target IOP (upwards or downwards) or to escalate treatment.
The reason for the over-ride was recorded.
Follow-up procedure
Follow-up intervals were set at entry to the study, based on disease severity and lifetime risk of loss of vision,
according to NICE guidance,15 and subsequently adjusted on the basis of IOP control, disease progression or
adverse reactions. Disease stability, along with all available data, was taken into consideration, but testing
for progression did not independently determine follow-up intervals. The routine schedule of appointments
for patients who remained at or below the target IOP, without progression or treatment change, and who
had no adverse reactions requiring earlier assessment, is shown in Table 2. Additional VF tests were
permissible at any visit if clinically necessary to confirm possible progression. Variation in follow-up intervals
was permitted to accommodate the clinician’s judgement and/or patient choice.56
Participants in the Laser-1st arm were reviewed 2 and 8 weeks after SLT application. After the 8-week
review in the Laser-1st group and for all treatment changes in the Medicine-1st arm, patients were
reviewed at 2 months, following which their treatment was changed (with consequent early assessment
of response to second treatment) or they entered a disease severity-tailored routine follow-up schedule.
Follow-up of patients with severe OAG was at the discretion of the consultant ophthalmologist. If an eye
showed ‘possible progression’, then the follow-up frequency was increased to every 3–4 months until
progression was confirmed or ruled out with additional VF testing or HRT. No further tests were conducted
at additional visits for IOP check alone. All contacts with medical professionals and optometrists were
captured for cost data. Information on contact with health-care providers was collected via the CSRI,
a validated method of collecting health-care cost data.63
Follow-up intervals were planned within the ranges specified by NICE guidance15 and were independently
determined on the basis of IOP control or adverse reactions, to minimise bias. The main driver for follow-up
frequency was treatment in pursuit of control. Disease stability was considered using all available data,
but testing for progression did not independently determine follow-up. Patients who required medication
TABLE 2 Routine follow-up frequency for patients who remain at target without progression or treatment change
and have no adverse effects requiring earlier assessment
Disease severity
category First visit
Routine follow-up intervals in months
Second
visita
Third
visit
Fourth
visit
Fifth
visit
Sixth
visit
Seventh
visit
Eighth
visit
OHT Randomisation
and treatment
2 4 6 12 12 12 12
Mild OAG 2 4 6 6 12 12 12
Moderate OAG 2 4 6 6 6 6 6
Severe OAG 1–2 4 6 6 6 6 6
a All patients are seen 2 months after randomisation and initial treatment. Patients treated with SLT are also seen 2 weeks
post treatment for an IOP check (not shown in this table).
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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changes or additional laser treatment and patients who suffered AEs or showed progression of glaucoma
were seen sooner and reverted to schedule when stable. The worse or more unstable of each patient’s
two eyes determined the follow-up interval, whereas treatment was individualised to the needs of each eye.
Follow-up clinical assessments
The schedule of assessments (all assessments were part of routine care) is shown in Table 3. After the full
baseline assessment, all patients underwent VF testing and HRT to assess progression at each follow-up
visit. The EuroQol-5 Dimensions (EQ-5D-5L) and other HRQoL questionnaires were assessed at baseline and
6-monthly thereafter, with additional questionnaires as outlined in Questionnaires.
Questionnaires
The content of the questionnaires was determined by the use of a number of validated, widely accepted
existing questionnaires as follows:
l EQ-5D-5L
l GUI
l GSS
l GQL-15.
TABLE 3 Schedule of assessments and questionnaires for the baseline and follow-up visits for patients who remain
at target without progression or treatment change and have no adverse effects requiring earlier assessment
Investigation
Time of follow-upa
Baseline
First
checka
Third visit
(6 months)
First
year 18 months
Second
year
Patient
specificb
Third
year
Clinical examination
(including disc and IOP)
Yes Yes Yes Yes Yes Yes Yes Yes
Dilated fundus
examination
Yes – Yes Yes Yes Yes Yes Yes
Gonioscopy Yes – – – – – – Yes
VF test Yes – Yes Yes Yes Yes Yes Yes
Optic nerve imaging
(HRT)
Yes – Yes Yes Yes Yes Yes Yes
EQ-5D-5L Yes – Yes Yes Yes Yes – Yes
GUI Yes – Yes Yes Yes Yes – Yes
GSS Yes – Yes Yes Yes Yes – Yes
CSRIc Yes – Yes Yes Yes Yes – Yes
a First follow-up visit was at 2 weeks following SLT, followed by a visit at 2 months. First follow-up visit for the Medicine-1st
pathway was at 2 months.
b Follow-up frequency may have varied depending on clinical findings at each visit.
c Modified CSRI questionnaire.
Notes
Additional VF tests were permissible at any visit, if clinically necessary to confirm possible progression. Variation in follow-up
intervals was permitted to accommodate clinician’s judgement and/or patient choice.
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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Additionally, a modified CSRI was used and two questions regarding concordance. The content of the
questionnaires used can be found as supplementary material [see URL: www.journalslibrary.nihr.ac.uk/
programmes/hta/0910440/#/documentation (accessed 23 April 2019)]; a sample of each questionnaire
completed is presented in Appendix 5. The patient and public involvement group reviewed the final
questionnaire for layout and clarity to ensure ease of completion.
Questionnaire delivery and follow-up
The baseline questionnaires were self-completed by participants in a private room, at the time of
enrolment, after informed consent had been given but before randomisation. Participants were required to
have sufficient English knowledge that translation was not required [practical assistance with the layout
(e.g. some questionnaires were printed double-sided, some questions had conditional formatting
depending on the patients’ response) and completion of the form were permitted].
Subsequent questionnaires were sent out by post for self-completion at 6-monthly intervals; up to two
written reminders followed by one telephone follow-up were implemented in the case of non-response.
In the event of a telephone follow-up, if the patient was willing, only the primary outcome measure was
collected. Aiming to incentivise LiGHT participants to return the vital final questionnaire, a high street
voucher worth £5.00 was sent by post along with the final set of questionnaires to each participant.
The central site at MEH managed all questionnaires across all collaborating sites.
Follow-up has been extended beyond the primary study to look additionally at HRQoL outcomes at 6 years;
questionnaires are will be posted to participants every 6 months for the duration of the extended period.
Adverse events and serious adverse events
An AE was defined as an unfavourable medical occurrence in a patient that was not necessarily caused by
the treatment. GCP guidelines67 were used to determine if AEs should be classified serious [serious adverse
events (SAEs)]. AEs and SAEs were reported in accordance with standard operating procedures (SOPs) and
GCP guidelines, to achieve standardisation across sites and between treatment arms, with an annual safety
report to the Research and Ethics Committee.
Primary outcome measure
The primary outcome measure was HRQoL in patients with OAG or OHT treated with SLT first, compared
with HRQoL in patients treated with topical medication first, measured using EQ-5D-5L utility scores at
3 years.
Secondary outcome measures
The secondary outcomes were as follows:56
l Treatment pathway health-care resource use, cost and cost-effectiveness. Health-care resource use was
ascertained from the record of treatment episodes and additional health-care contacts using a modified
CSRI.63 The cost components included the cost of SLT, number of visits, number and type of medications
and glaucoma surgeries, and clinical tests.
l Glaucoma-specific treatment-related QoL was measured using the GUI, from which quality-adjusted
life-years (QALYs) can also be derived.
l Patient-reported disease and treatment-related symptoms using the GSS.
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l Patient-reported visual function using the GQL-15.
l Objective measurements of pathway effectiveness for IOP-lowering and visual function preservation
(e.g. treatment intensity and time taken to achieve target IOP, the number of target IOP revisions,
proportion of patients achieving target after each year of treatment, number of patients with confirmed
disease deterioration and rates of ocular surgery).
l Objective safety measures for each pathway.
l Concordance assessed by two questions shown to predict the probability of non-concordance.80
Reproduced with permission from The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A
multicentre randomised controlled trial: baseline patient characteristics, Konstantakopoulou E, Gazzard G,
Vickerstaff V, Jiang Y, Nathwani N, Hunter R, Ambler G, Bunce C, volume 102, pp. 599–603, 2018 with
permission from BMJ Publishing Group Ltd.72
Data collection and management
To standardise data collection and management, researchers were trained to follow specific SOPs for each
stage of data handling. Identical electronic and hard-copy case report forms (CRFs) were designed according
to a standard CRF template. A web-based database for the Priment Clinical Trials Unit, managed by the
company ‘SealedEnvelope’, was used for database entry with direct data entry at the time of patient visit.
This included extensive internal consistency and range checking, with a hard-copy backup CRF in case of
information technology (IT) failure. Records were identifiable only by unique, confidential trial identification
number with no patient-identifiable information included. All data were contemporaneously entered
directly into the web-based database CRF.
Data from patient completed questionnaires received by post were scanned on receipt for e-copy back-up
and entered onto the database within 1 week of receipt by the trial data management officer. Questionnaire
data were from validated, standardised tools (EQ-5D-5L, GUI, GQL-15, GSS and CSRI) (see Table 3). The
central site at MEH managed the inputting of data from all questionnaires across all collaborating sites.
Statistical analysis plan
The statistical analysis plan has been published previously.81 All patients were analysed in the treatment
arm to which they were randomised. All analyses were performed in Stata® version 14 (StataCorp LP,
College Station, TX, USA).
Sample size
The sample size for the study was 718 participants. This number of participants was required to detect a
difference of 0.05 in EQ-5D-5L between the two arms at 36 months using a two-sample t-test at the 5%
significance level, with 90% power, assuming a common standard deviation (SD) of 0.1982 and a 15% loss
to follow-up.81
Baseline
The baseline characteristics of each arm were summarised as means and SDs for continuous, symmetric
variables, medians and interquartile ranges (IQRs) for continuous, skewed variables and frequencies and
percentages for categorical variables. These summaries were based only on observed data. No significance
testing was performed.
Primary outcome
The primary outcome measure was HRQoL measured using the EQ-5D-5L at 36 months. The EQ-5D-5L
questionnaire was analysed using a linear regression model, with an adjustment for the randomisation
factors (severity and centre), baseline IOP, the baseline value of EQ-5D-5L and whether one or two eyes
were affected at baseline.
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For the primary outcome, the unit of analysis was the patient. If both of a patient’s eyes were included in
the study, we used the worse eye at baseline for severity and baseline IOP covariates. The worse eye was
defined using the MD at baseline, with the worse eye having the most negative MD.
The primary analysis used outcome data measured at 36 months. If these were missing, we imputed these
missing data using the outcome measured at 30 months.
Secondary outcomes
The secondary outcomes were analysed using regression methods appropriate for the type of outcome.
These models were also adjusted using the covariates mentioned above. The results from all secondary
analyses are presented as estimates with confidence intervals (CIs).
Exploratory analyses
We used mixed-effect models, using all patient outcome data over the 36 months, to investigate how the
primary and secondary outcomes changed over time. Such models allow the analysis of repeated outcome
measurements data (recorded every 6 months), as well as taking into account the correlation between
measurements from the same patient. Standard regression models assume independence between
observations, which typically means that separate models are required for each time point. The mixed-effect
models allowed modelling all time points (baseline and 6, 12, 18, 24, 30 and 36 months) in a single model,
by explicitly modelling both the within- and the between-patient variability.83
By using interaction terms between randomisation arm and time, we investigated differences between the
groups over time.
We also used a similar mixed-effect model using all patient data over the 36 months, to evaluate the
treatment effects at 36 months by using the exact times that the questionnaires were completed. Finally,
using all the patient data over the 36 months, we used a mixed-effects model to explore the average
treatment effect over the 36 months.
Analysis of missing data
Potential bias as a result of missing data was investigated by descriptively comparing the baseline
characteristics of the trial participants with complete follow-up measurements with those who had
incomplete follow-up or no outcome data.
Analysis of homogeneity
To explore the homogeneity (or otherwise) of the intervention effect on the primary outcome, we
examined the treatment effect across the following: age (as a continuous measure); severity of glaucoma
(using the two groups OHT/OAG used during randomisation process); baseline IOP (as a continuous
measure); and sex. The results from these analyses should be treated as exploratory and hypothesis
generating, as the trial was not powered for these analyses.
Sensitivity analyses
First, we ran sensitivity analyses that adjusted for variables associated with missingness. We performed
logistic regression analyses (with missing ‘yes’ or ‘no’ as the outcome), to identify predictors of missing
data. When predictors associated with both missing data and outcomes were found, we refitted the
primary analysis model, adjusting for these predictors of missingness.
Second, to take into account any missing data, we used a multiple imputation approach. The imputation
model included the outcome of interest, sociodemographic variables and any other variables potentially
related to missingness and HRQoL. The imputations were performed separately by treatment arm.
METHODS
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Economic evaluation
The aim of the economic evaluation was to calculate the mean incremental cost per QALY of Laser-1st
compared with Medicine-1st. Health and social care costs and QALYs were calculated for the within-trial
period (36 months). The outputs were:
l mean total patient-level QALYs by trial arm
l mean cost per patient of laser treatment in the Laser-1st arm
l mean cost per patient of eyedrop treatment for glaucoma by trial arm
l mean cost per patient of surgery by trial arm
l mean total health-care cost per patient over 3 years by trial arm
l mean increment cost per QALY of Laser-1st compared with Medicine-1st and 95% CIs
l cost-effectiveness planes
l cost-effectiveness acceptability curves (CEACs).
Quality-adjusted life-years
Mean patient-level QALYs by trial arm were calculated as the area under the curve using patient-level
responses to EQ-5D-5L at each follow-up time point84 and the formula by Devlin et al.85 Patients who died
were imputed as zero from the date of death until the end of the trial. We assumed a straight line from
the last follow-up time point until death. As the EQ-5D-5L is the primary outcome for the trial, mean
patient responses at each follow-up time point are reported as part of the repeated-measures analysis. The
mean incremental difference in QALYs was calculated using ordinary least squares regression and included
covariates for randomisation arm, baseline EQ-5D-5L values, randomisation factors (severity and centre),
baseline IOP and number of eyes affected at baseline.
Quality-adjusted life-years were discounted from 12 months to 3 years at an annual rate of 3.5%.86
Ninety-five per cent CIs were calculated using bootstrapping, bias corrected and 5000 replications, given
that we assume that the data are not normally distributed. Although there was a high rate of return for
the EQ-5D-5L at 36 months (91%), data were missing for each time point, which meant that only 73%
of patients had complete data across all time points for calculation of QALYs. Multiple imputation using
chained equations was used to impute the data for 35 data sets, including age, highest education attainment,
employment and diabetic status, included as variables identified as being predictive of missingness.
Cost of selective laser trabeculoplasty
The cost of SLT was calculated using bottom-up microcosting based on data collected from sites. Sites
reported the cost of the machine maintenance costs, how sessions were run (dedicated sessions for SLT or
as part of a routine session), the grade and number of staff for each session and the number of patients
treated per session and per year. Staff wages and overheads were taken from the Personal Social Services
Resource Unit (PSSRU).87 The cost per patient of using the machine was based on an annuitised formula,88
accounting for the number of patients seen in a ‘typical’ site per year and assuming a laser lifetime of
10 years. The number of SLTs per patient was reported.
Cost of drops for open-angle glaucoma and ocular hypertension
We report the mean cost of eyedrops by trial arm over 3 years. Information on eyedrops prescription,
including drug name, dose, number of eyes, number of drops per eye and frequency, was collected as part
of trial monitoring processes. Each prescription was costed using the British National Formulary (2018) to
calculate the cost per bottle.89 This was divided by the number of drops per bottle to calculate the cost per
day. To calculate the number of days per medication, it was assumed that patients would take the medication
from the day of prescription until the next medication change. The mean total cost per patient was then the
cost per day of the prescribed eyedrops multiplied by the number of days the medication was prescribed for.
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Total ophthalmology-related costs
In addition to eyedrops and laser, information was collected from the patient files on ocular surgery and
planned and unplanned specialist ophthalmologist visits. These included a 2-week IOP check as part of the
trial process; however, this check would not occur if the service was rolled out and hence this IOP check
was removed from the primary analysis. Descriptive statistics for ophthalmology resource use are reported in
Chapter 3, Ocular-related costs. Ocular surgery and ophthalmologist outpatient appointments were costed
using the NHS Reference Costs 2016–17.90 We report the mean cost per patient at 3 years for each type of
ophthalmology cost, as well as total costs discounted at an annual rate of 3.5%86 by trial arm. Ninety-five
per cent bias-corrected CIs were calculated using bootstrapping and 5000 replications. Given that data
were taken from patient files, it was not possible to identify missing data (it was assumed that if patients did
not have an appointment or surgery reported, this was because none occurred). As a result, the intention to
treat (ITT) was based on all the patients, assuming that the appointment data collected are correct.
Other health-care costs
Health-care resource use, including optician contacts, community health-care contacts and acute health-
care contacts, was collected from a modified version of the CSRI91 at baseline and at 6, 12, 18, 24, 30 and
36 months, asking about eye-related and non-eye-related resource use in the past 6 months. Information
on inpatient stays and day cases was checked against SAE data. SAEs not reported in the CSRI were
included in the total inpatient cost. Resource use was costed using unit costs from PSSRU87 except for
optometrist visits,92 heart bypass surgery90 and cancer deaths (Table 4).93 Mean costs by trial arm at each
time point were by ocular- and non-ocular-related costs over 3 years.
Total health and social care costs
The cost components included in the analysis were the cost of SLT, OAG medication and other health-care
costs. We report the mean cost per patient in addition to an adjusted cost, adjusting for baseline service
use using regression analysis. Mean costs were based on a complete-case analysis, with only optician and
CSRI resource use excluding inpatient stays missing (an analysis imputing for missing CSRI data using
chained equations has been included). The mean incremental difference in costs is calculated using
ordinary least squares regression and includes covariates for randomisation arm, baseline EQ-5D-5L values,
randomisation factors (severity and centre), baseline IOP and number of eyes affected at baseline. We used
bias-corrected bootstrapping to calculate 95% CIs, given that we assumed that the data are not normally
distributed. All costs are reported in 2016/17 Great British pounds.
Incremental cost-effectiveness ratio
The incremental cost-effectiveness ratio (ICER) was defined as the mean incremental cost of Laser-1st
compared with Medicine-1st and divided by the mean incremental QALYs of laser treatment compared
with eyedrops. The mean incremental differences were adjusted for baseline values, randomisation factors
(severity and centre), baseline IOP and number of eyes affected at baseline. To account for the correlation
between costs and QALYs, seemingly unrelated regression was used to calculate the numerator and
denominator of the ICER. ICERs are reported for total costs, as defined in Total health and social care
costs, and ophthalmology only costs, as defined in Total ophthalmology-related costs. Costs and QALYs
from 12 months until 36 months are discounted at an annual rate of 3.5%.86 The final results for total
costs and QALYs are based on data imputed using chained equations for QALYs and CSRI, and using the
missing at random methodology described in Leurent et al.57 for calculating CEACs using bootstrapping
and multiple imputation for 200 draws of each of the 35 imputed data sets for 7000 replications in total.
Cost-effectiveness acceptability curve
A CEAC is reported using the bootstrap imputed data (200 draws of each of the 35 imputed data sets for
7000 replications in total), for a range of values of willingness to pay for a QALY. We report the probability
that Laser-1st is cost-effective compared with Medicine-1st at a willingness to pay for a QALY of £20,000
and £30,000 for (1) total costs and (2) ophthalmology only costs.
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Secondary analyses
The following secondary analyses were conducted:
l For the primary analysis SLT was costed using microcosting. Some assumptions of the microcosting, for
example the number of patients per site per year, or how sessions are run, may have an impact on the
total cost. As a result, we planned to examine the impact of modifying the assumptions on the total
cost of SLT per patient and hence the ICER. The cost of SLT as estimated from NHS reference costs90
was used in the analysis.
l In the primary analysis we removed the cost of the 2-week IOP check, given that this was unlikely to
occur in practice. One could hypothesise that patients obtained some minor benefit from this check and
hence its costs could be included in the analysis. A secondary analysis including the 2-week IOP check
has been included.
l QALYs were calculated using utility scores generated from the GUI61 and the same methodology for
calculating QALYs as above. The results were combined with the costs, as above, to report the mean
incremental cost per QALY of Laser-1st compared with Medicine-1st, using the GUI.
TABLE 4 Health-care unit costs used in the cost-effectiveness analysis
Resource use Unit cost (£) (per contact) Source
Trabeculectomy 1436 NHS Reference Costs 2016–1790
Ophthalmology appointments 91 NHS Reference Costs 2016–1790
Optometrist visit 52 Violato et al.92
Planned inpatient stay 3903 Curtis87
Unplanned inpatient stay: short durationa 628 Curtis87
Unplanned inpatient stay: long durationb 2953 Curtis87
A&E attendance: admitted 221 NHS Reference Costs 2016–1790
A&E attendance: not admitted 128 NHS Reference Costs 2016–1790
Outpatient attendance 137 Curtis87
GP contact: in practice 31 Curtis87
GP contact: telephone 24 Curtis87
GP contact: at home 80 Curtis87
GP practice nurse 36 Curtis87
Social care 59 Curtis87
Home care 26 Curtis87
Other community contacts 57 NHS Reference Costs 2016–1790
Cancer death 6129 Georghiou and Bardsley93
A&E, accident and emergency; GP, general practice.
a < 7 days.
b ≥ 7 days.
Note
All costs are reported in 2016/17 Great British pounds.
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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Patient and public involvement: lay advisory group
Glaucoma patients and relatives from the Cochrane Eyes and Vision Group Consumer Panel formed our
independent LAG. Consultation on trial design, choice of outcome measures, recruitment and treatment
acceptability took place by e-mail and through online discussions via the Facebook social networking site
(Facebook, Inc., Menlo Park, CA, USA; Group: ‘Public Eye – LiGHT Trial Discussion Forum’). All of the
suggestions made have been incorporated (e.g. requests to monitor all symptoms in detail, a safety
concern about ‘rapid loss of pressure control’ after SLT and more explanation of the relationship between
eyedrops and surgical failure). An ‘expert patient’ with treated glaucoma reviewed and commented on the
study protocol as a service user member for the Trial Steering Committee (TSC) and another service user
representative from the International Glaucoma Association was invited to join. The LAG contributed to
the development of tailored information leaflets and consent forms with further consultation with service
user groups and via the Friends of Moorfields charity. A survey of 100 new patients attending MEH to
assess the acceptability of an invitation to participate in such a trial, before the commencement of the trial,
had a 70% positive response.
Patients diagnosed and treated for glaucoma also provided input to a questionnaire sent in 2015 (see
Appendix 6), allowing us to design an extension for the main LiGHT trial; the questionnaire looked into the
views of these treated patients on current treatment options and their willingness to switch from eyedrops
to laser.
As required by the NHS, in line with INVOLVE national guidelines and in accordance with UK Clinical
Research Collaboration policy, the results are being communicated to patients, for example via NHS
Choices and patient advocate groups (e.g. International Glaucoma Association), and the findings have
been published in open access media.58
Study oversight and management
Study co-ordination in London
The Trial Management Team was composed of the chief investigator, central trial manager (CTM),
central trial optometrist (CTO), central research optometrist (CRO), lead trial statistician and trial statistician,
members of the University College London Priment Clinical Trials Unit, trial data officers, co-applicants
and trial optometrists. The team met monthly on average to ensure the smooth running of the trial and
troubleshooting. The duties of the CTM were to support the organisation of the study [investigator meetings,
TSC and Data Management Committee (DMC) meetings, training, etc.] and have a study management
role, including monitoring data collection according to established milestones, maintaining trial records,
co-ordinating data management between local sites and the central clinical trial unit, facilitating user
involvement in the project through LAG meetings and working alongside the CTO and facilitating the
recruitment and follow-up of study participants.
Local organisation in centres
The chief investigator (consultant ophthalmologist) was the local PI at the central site (MEH), who
co-ordinated the local ethics approval and sat on the TSC. The local study co-ordinator administrated the
follow-up and recall of patients, liaising with the Trial Management Team. The local trial clinicians were
an ophthalmologist, a fellow or an optometrist who were responsible for the recruitment, treatment and
follow-up of trial participants. They had regular conference calls with the Trial Management Team for the
duration of the study. The local trial clinicians were directly accountable to the local PIs. There were regular
conference calls to all local clinicians and PIs to troubleshoot local issues. The chief investigator closely
supervised the CTM, CTO and CRO with regular meetings.
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Trial Steering Committee
The TSC was composed, in accordance with GCP, of an ophthalmologist as the independent TSC
chairperson, a chief investigator, an independent clinician with relevant expertise, a sponsor representative,
a Central and East London Comprehensive Local Research Network representative, an independent health
economist, an independent statistician and two patient representatives. The trial manager, chief investigator,
lead trial statistician and trial statistician were invited to report as required. The TSC met at least 6-monthly
and minutes were taken.
Data and safety monitoring
Data and safety monitoring by the University College London Priment Clinical Trials Unit involved regular
reports from the CTM, including recruitment and drop-out rates, adherence to SOPs, number failing to
meet target or progressing, and AEs. The chief investigator maintained day-to-day responsibility for the
trial with the CTM to ensure that the trial was conducted, recorded and reported in accordance with the
protocol, GCP94 guidelines and SOPs.
The DMC was composed of the following individuals in accordance with GCP guidelines: (1) a DMC
chairperson, (2) an independent trial statistician and (3) two additional glaucoma or ophthalmic trials
specialists. The DMC met annually (or more often if appropriate), timed to report to the TSC. During
recruitment, interim reports were supplied to the DMC, together with any analyses it requested.
The above committees followed SOPs set by MEH and the University College London Priment Clinical Trials
Unit, and complied with guidelines issued by the National Institute for Health Research (NIHR) Health and
Technology Assessment panel for clinical trials.
Data monitoring
We completed double data entry for the EQ-5D-5L for all completed questionnaires for all time points. The
second data entry was completed by a different individual to the person doing the first entry. The first data
entry was then matched with the second data entry and any discrepancies were checked and resolved by
referring back to the hard-copy questionnaire.
The trial research team performed checks on 100% of the clinical baseline and eligibility data. Monitoring
activity across sites was carried out at scheduled intervals and was adapted to the demonstration of errors
by the collaborating sites (see Appendix 7). Protocol deviations and violations were recorded throughout
the study and appropriate action was taken to prevent similar events from taking place in the future.
Protocol amendments
A series of minor amendments have taken place after the commencement of the trial and were submitted
to the funder, as well as gaining ethics approval. Below is a list of the major protocol amendments:
1. addition of audio-visual material to assist with recruitment of patients
2. collection of blood, tears and saliva samples
3. addition of the ocular response analyser (Reichert Ophthalmic Instruments, Inc., Buffalo, NY, USA) to
the assessments
4. extension of the trial to 6 years
5. ocular surface disease questionnaire (extension only).
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Chapter 3 Results
The main results of the study have been published in Gazzard et al.58 © 2019 The Author(s). Publishedby Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence (http://creativecommons.org/
licenses/by/4.0/).
Recruitment
A total of 16,379 patients were assessed for eligibility; 15,483 were excluded as they did not meet the
inclusion criteria. Of the 896 patients who were eligible across the six participating NHS centres, a total of
718 (1235 eyes) were recruited for the study (80.1% participation rate). A recruitment chart for the total
recruitment period can be found in Appendix 8. A total of 178 eligible patients declined to participate.
Of the patients who declined to participate, 43 did not want to have SLT, 17 did not want to take part in
research, nine did not want to use eyedrops, three did not want to receive any treatment, one did not
want to travel to the hospital and 105 did not provide an explanation.
Participant flow
A total of 718 patients (1235 eyes) were randomised: 356 patients (613 eyes) were allocated to SLT
(Laser-1st pathway) and 362 patients (622 eyes) to medical treatment (Medicine-1st pathway) (Figure 4).
Two patients were randomised twice owing to failure, as a result of which the initial randomisation was
not visible. Subsequently, a second randomisation was carried out; one of these patients had initially
been randomised to medication (non-visible randomisation), but was subsequently randomised to, and
received, SLT. The second patient was initially randomised to SLT (non-visible randomisation), but was
later randomised to, and received, medication. Four patients who did not meet the eligibility criteria were
randomised in error and were subsequently removed from the study (see Appendix 9).
Participant baseline characteristics
Reproduced with permission from The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A
multicentre randomised controlled trial: baseline patient characteristics, Konstantakopoulou E, Gazzard G,
Vickerstaff V, Jiang Y, Nathwani N, Hunter R, Ambler G, Bunce C, volume 102, pp. 599–603, 2018 with
permission from BMJ Publishing Group Ltd.72
Participant baseline characteristics are shown in Table 5. Of the 718 patients recruited, approximately 70%
were based in London: 52% were recruited by MEH and almost 15% from Guy’s and St Thomas’ Hospital.
The average age of the patients was 63.1 years (± 11.8 years), with more male patients recruited than female
(55.3% male vs. 44.7% female). In total, 70% of all participants were white, and black was the second
largest ethnic group (20%). Thirty per cent of patients reported a family history of glaucoma affecting at least
one first-degree relative. Systemic hypertension (defined as the use of prescribed antihypertensive medication)
was recorded in 35% of the patients. Use of systemic antihypertensive medication was recorded in these
patients; of those, 5% were using beta-blockers, 16% were using calcium channel blockers and 14% were
using angiotensin-converting enzyme inhibitors; 27% of all patients were on statins. In total, 11% of the
patients were smokers at the time of recruitment. Approximately 30% of the LiGHT patients had a degree
or equivalent qualification, 13% had achieved higher education, 12% had achieved Advanced Level or
equivalent and 45% did not pursue an education beyond 16 years of age.
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Analysed
(n = 329)
• Did not return the primary outcome at
   36 months, n = 11
Discontinued participation
(n = 16)
• Was no longer contactable, n = 1
• Moved to another hospital, n = 1
• Withdrew from the trial, n = 3
• Deceased, n = 8
• Ill health and unfit to continue, n = 3
Allocated to Laser-1st (SLT)
(n = 356)
• Received allocated intervention, n = 355
• Withdrew consent before treatment, n = 1
Analysed
(n = 323)
• Did not return the primary outcome at
   36 months, n = 30
Discontinued participation
(n = 9)
• Was no longer contactable, n = 1
• Moved to another hospital, n = 3
• Withdrew from the trial, n = 1
• Deceased, n = 2
• Ill health and unfit to continue, n = 2
Allocated to Medicine-1st
(n = 362)
Randomiseda
(n = 718)
Patients assessed for eligibility 
(n = 16,379)
Excluded
(n = 15,661)
• Received allocated intervention, n = 361
• Decided to receive SLT after
   randomisation, n = 1
• Did not meet inclusion criteria, n = 15,483
• Declined to participate, n = 178
   • Did not want to have SLT, n = 43
   • Did not want to take part in research, n = 17
   • Did not want to use eyedrops, n = 9
   • Did not want any treatment, n = 3
   • Did not want to travel to the hospital, n = 1
   • Did not provide an explanation, n = 105
FIGURE 4 The LiGHT trial Consolidated Standards of Reporting Trials (CONSORT) flow diagram. a, Two patients
were randomised twice owing to IT failure, as a result of which the initial randomisation was not visible, and
subsequently a second randomisation was carried out. Reproduced from Gazzard et al.58 © 2019 The Author(s). Published
by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
TABLE 5 Baseline patient demographic characteristics
Characteristic
Total (N= 718),
n (%)
Medicine-1st (N= 362),
n (%)
Laser-1st (N= 356),
n (%)
Centre
MEH 374 (52.1) 187 (51.7) 187 (52.5)
Hinchingbrooke Hospital 82 (11.4) 41 (11.3) 41 (11.5)
Guy’s and St Thomas’ Hospital 106 (14.8) 55 (15.2) 51 (14.3)
Queen’s University Belfast 30 (4.2) 15 (4.1) 15 (4.2)
Norfolk and Norwich University Hospital 89 (12.4) 46 (12.7) 43 (12.1)
York Hospital 37 (5.2) 18 (5.0) 19 (5.3)
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TABLE 5 Baseline patient demographic characteristics (continued )
Characteristic
Total (N= 718),
n (%)
Medicine-1st (N= 362),
n (%)
Laser-1st (N= 356),
n (%)
Age (years), mean (SD) 63.1 (11.8) 62.7 (11.6) 63.4 (12.0)
Sex, n (%)
Male 397 (55.3) 197 (54.4) 200 (56.2)
Female 321 (44.7) 165 (45.6) 156 (43.8)
Ethnicity, n (%)a
Asian 51 (7.1) 28 (7.7) 23 (6.5)
Black 146 (20.3) 69 (19.1) 77 (21.6)
White 501 (69.8) 258 (71.3) 243 (68.3)
Other 20 (2.8) 7 (1.9) 13 (3.7)
Diagnosis, n (%)
OAG 555 (77.3) 282 (77.9) 273 (76.7)
OHT 163 (22.7) 80 (22.1) 83 (23.3)
General health conditions, n (%)
Asthma 93 (13.0) 45 (12.4) 48 (13.5)
Hypertension 251 (35.0) 119 (32.9) 132 (37.1)
Diabetes 82 (11.4) 40 (11.1) 42 (11.8)
Angina 21 (2.9) 11 (3.0) 10 (2.8)
Cardiac arrhythmia 37 (5.2) 20 (5.5) 17 (4.8)
Medication, n (%)
Statins 196 (27.3) 92 (25.4) 104 (29.2)
Systemic beta-blockers 34 (4.7) 12 (3.3) 22 (6.2)
Calcium channel blocker 116 (16.2) 60 (16.6) 56 (15.7)
ACE inhibitors 100 (13.9) 43 (11.9) 57 (16.0)
Corticosteroids 42 (5.9) 20 (5.5) 22 (6.2)
Family ocular history of glaucoma,b n (%) 214 (30.0) 107 (29.6) 107 (30.1)
Highest education achievement, n (%)
Degree or equivalent 216 (30.1) 106 (29.3) 110 (30.9)
Higher education 94 (13.1) 39 (10.8) 55 (15.5)
A level or equivalent 88 (12.3) 49 (13.5) 39 (11.0)
GCSE 155 (21.6) 84 (23.2) 71 (19.9)
Other qualifications 59 (8.2) 30 (8.3) 29 (8.2)
No qualification 106 (14.8) 54 (14.9) 52 (14.6)
ACE, angiotensin-converting enzyme; A level, Advanced level; GCSE, General Certificate of Secondary Education.
a Self-defined ethnicity: ‘Asian’ ethnicity refers to Indian, Pakistani, Bangladeshi and any other Asian background, ‘black’
ethnicity refers to Caribbean, African and any other black background, and ‘other’ ethnicity refers to Chinese and any
other ethnic groups.
b First-degree relative.
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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A total of 301 patients (41.9%) had bilateral OAG, 161 patients (22.4%) had unilateral OAG (fellow eye
healthy), 93 patients (13.0%) had OAG in one eye and OHT in the other eye, 124 patients (17.3%) had
bilateral OHT and 39 patients (5.4%) had unilateral OHT (fellow eye healthy). A total of 555 patients
(77.2%) were classified as having OAG (if at least one eye was affected by OAG) and 163 patients
(22.7%) were classified as having OHT; both eyes were eligible for the trial in 517 patients (72.0%),
only the right eye was eligible in 96 patients (13.4%), and only the left eye was eligible in 105 patients
(14.6%); 55% of the better eyes were right eyes.72
The baseline patient characteristics were similar between the two groups in terms of age, sex distribution,
ethnicity, general health and family history of glaucoma (see Table 5). There were small differences in the
medication and education of the patients. The eye characteristics were also similar between the two
treatment arms, with VA, VF MD, HRT optic disc rim area, IOP and CCT comparable between the two
treatment arms (Table 6).
The baseline scores for QoL (EQ-5D-5L, GSS, GUI and GQL-15) are shown in Table 7. The two treatment
arms had similar average EQ-5D-5L scores (Medicine-1st 0.92 ± 0.13, Laser-1st 0.91 ± 0.13; higher scores
indicate better HRQoL), GUI scores (Medicine-1st 0.89 ± 0.11, Laser-1st 0.89 ± 0.12; higher scores indicate
better HRQoL) and GQL-15 scores (Medicine-1st 18.7 ± 5.6, Laser-1st 18.9 ± 6.6; higher scores indicate
worse HRQoL) at baseline. The Medicine-1st arm showed slightly higher average GSS scores at baseline than
the Laser-1st arm (Medicine-1st 83.3 ± 16.6, Laser-1st 81.4 ± 17.2; higher scores indicate better HRQoL).
Primary outcome return rates
A total of 652 patients returned the primary outcome at the trial’s end point at 36 months (overall return rate
was 91%: 92% for the SLT arm and 89% for the Medicine-1st arm), and were included in the ITT analysis
(with imputation used for missingness). An additional 21 patients supplied 30-month data, which was used to
impute their missing 36-month data, such that 673 patients were included in the primary ITT analysis.
TABLE 6 Baseline patient clinical characteristics
Characteristic N All eyes (N= 1235) Medicine-1st (N= 622) Laser-1st (N= 613)
Diagnosis, n (%)
OHT 380 (30.8) 185 (29.7) 195 (31.8)
Mild OAG 636 (51.5) 325 (52.3) 311 (50.7)
Moderate OAG 144 (11.7) 77 (12.4) 67 (10.9)
Severe OAG 75 (6.1) 35 (5.6) 40 (6.5)
Refractive error (spherical D), mean (SD) 1225 –0.23 (3.0) –0.2 (2.7) –0.3 (3.2)
VA, mean (SD) 1235 0.1 (0.12) 0.1 (0.1) 0.1 (0.2)
VF MD (dB), mean (SD) 1233 –3.0 (3.45) –3.0 (3.6) –3.0 (3.4)
HRT rim area, mean (SD) 1128 1.2 (0.4) 1.1 (0.4) 1.2 (0.4)
IOP, mean (SD) 1233 24.5 (5.1) 24.4 (5.0) 24.5 (5.2)
CCT (µm), mean (SD) 1229 551.1 (37.2) 551.6 (36.3) 550.7 (38.1)
PXF, n (%) 1233 17 (1.4) 12 (1.9) 5 (0.8)
Pseudophakia, n (%) 1233 72 (5.8) 33 (5.3) 39 (6.4)
PXF, pseudoexfoliation syndrome.
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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Losses to follow-up
A total of 16 patients in the Laser-1st arm and nine patients in the Medicine-1st arm discontinued
participation (see Figure 4). In total, two patients were lost to follow-up and were no longer contactable,
four patients moved to a different hospital, four patients withdrew from the trial, five patients could not
continue participation owing to ill health and 10 patients died.
Quality of life
Primary outcome: EQ-5D-5L
At 36 months, the Laser-1st arm had an average EQ-5D-5L score of 0.90 (SD 0.16), compared with
0.89 (SD 0.18) in the Medicine-1st arm, suggesting little difference between the two treatment arms [adjusted
mean difference (Laser-1st –Medicine-1st) 0.01, 95% CI –0.01 to 0.03; p = 0.23] (Table 8 and Figure 5).
TABLE 7 Baseline questionnaire scores
Measure
Overall (N= 717),
mean (SD)
Medicine-1st (N= 362),
mean (SD)
Laser-1st (N= 355),
mean (SD)
EQ-5D-5L index 0.91 (0.13) 0.92 (0.13) 0.91 (0.13)
GUIa 0.89 (0.12) 0.89 (0.11) 0.89 (0.12)
GSSb 82.4 (16.9) 83.3 (16.6) 81.4 (17.2)
Subscales
Symptom 80.2 (19.7) 81.2 (19.4) 79.1 (20.1)
Function 85.6 (17.6) 86.4 (17.3) 84.8 (17.8)
GQL-15a 18.8 (6.1) 18.7 (5.6) 18.9 (6.6)
Subscales
Central 2.5 (1.0) 2.5 (1.0) 2.5 (1.0)
Peripheral 8.5 (3.1) 8.4 (2.9) 8.5 (3.4)
Dark 7.9 (2.9) 7.9 (2.8) 7.9 (3.0)
Outdoor 1.1 (0.4) 1.1 (0.4) 1.1 (0.4)
a n = 716.
b n = 710.
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
TABLE 8 Primary (at 36 months) and secondary (across 36 months) analysis of HRQoL questionnaires
Measure
Medicine-1st Laser-1st
Adjusted mean
differencea 95% CI p-valuen Mean (SD) n Mean (SD)
Primary analysis at 36 months
EQ-5D-5L 336 0.89 (0.18) 337 0.90 (0.16) 0.01 –0.01 to 0.03 0.230
GUI 299 0.89 (0.13) 303 0.89 (0.13) 0.01 –0.01 to 0.03
GSS 281 83.3 (17.3) 294 83.1 (17.7) 1.6 –0.8 to 4.0
GQL-15 297 19.8 (7.8) 304 19.8 (7.2) –0.4 –1.3 to 0.6
QALY 263 2.70 (0.42) 261 2.74 (0.37) 0.025 0.02 to 0.07 0.289
QALY (discounted) 263 2.62 (0.41) 261 2.65 (0.36) 0.024 –0.02 to 0.07 0.286
continued
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TABLE 8 Primary (at 36 months) and secondary (across 36 months) analysis of HRQoL questionnaires (continued )
Measure
Medicine-1st Laser-1st
Adjusted mean
differencea 95% CI p-valuen Mean (SD) n Mean (SD)
Repeated measures analysis across 36 months
EQ-5D-5L
Baseline 362 0.92 (0.13) 355 0.91 (0.13)
6 months 332 0.90 (0.15) 330 0.91 (0.13) 0.01 –0.01 to 0.03
12 months 327 0.91 (0.14) 327 0.91 (0.14) 0.01 –0.01 to 0.02
18 months 329 0.90 (0.16) 325 0.90 (0.16) 0.00 –0.02 to 0.02
24 months 326 0.91 (0.14) 326 0.91 (0.14) –0.00 –0.02 to 0.02
30 months 320 0.90 (0.15) 317 0.90 (0.15) 0.00 –0.01 to 0.02
36 months 323 0.89 (0.18) 329 0.90 (0.16) 0.02 –0.00 to 0.03
GUI
Baseline 361 0.89 (0.11) 355 0.89 (0.12)
6 months 330 0.90 (0.11) 329 0.91 (0.10) 0.01 –0.00 to 0.03
12 months 315 0.89 (0.12) 320 0.91 (0.11) 0.01 –0.00 to 0.03
18 months 305 0.89 (0.12) 303 0.90 (0.13) 0.01 –0.01 to 0.02
24 months 298 0.89 (0.12) 305 0.90 (0.11) 0.02 0.00 to 0.03
30 months 299 0.88 (0.12) 291 0.89 (0.12) 0.02 0.00 to 0.03
36 months 300 0.89 (0.13) 303 0.89 (0.13) 0.01 –0.01 to 0.02
GSS
Baseline 357 83.3 (16.6) 353 81.4 (17.2)
6 months 321 83.0 (16.3) 320 85.6 (14.9) 4.0 2.0 to 6.0
12 months 310 83.0 (17.6) 309 85.2 (15.4) 2.9 0.8 to 4.9
18 months 295 83.1 (16.8) 294 84.6 (15.8) 2.8 0.7 to 4.8
24 months 287 83.3 (16.4) 290 83.3 (16.3) 1.4 –0.7 to 3.5
30 months 288 81.3 (17.6) 276 84.1 (16.7) 3.5 1.5 to 5.6
36 months 282 83.3 (17.3) 296 83.1 (17.7) 2.2 0.1 to 4.2
GQL-15
Baseline 361 18.7 (5.6) 355 18.9 (6.6)
6 months 323 18.8 (5.6) 324 18.3 (5.4) –0.8 –1.6 to 0.0
12 months 314 19.2 (7.2) 318 18.8 (6.6) –0.5 –1.4 to 0.3
18 months 302 19.1 (6.4) 298 18.9 (6.5) –0.6 –1.4 to 0.2
24 months 289 19.5 (7.3) 298 19.2 (6.7) –0.5 –1.3 to 0.4
30 months 293 19.9 (7.1) 287 19.6 (7.9) –0.3 –1.1 to 0.5
36 months 298 19.8 (7.8) 304 19.8 (7.2) –0.4 –1.2 to 0.4
a Laser-1st –Medicine-1st. Mean difference is adjusted for baseline score, severity, centre, baseline IOP and number of
eyes affected at baseline.
Notes
EQ-5D-5L: higher scores represents a better QoL.
GUI: higher scores represents a higher QoL.
GSS: higher scores represent better outcomes.
GQL-15: higher sores represents poorer glaucoma QoL.
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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FIGURE 5 Mean (a) EQ-5D-5L, (b) GUI, (c) GSS and (d) GQL-15 scores at each time point, across 36 months. Time
point ‘0’ refers to pre-treatment. a, Higher scores on EQ-5D-5L, GUI and GSS indicate better HRQoL; b, higher
scores on GQL-15 indicate worse HRQoL. Adapted by permission from BMJ Publishing Group Limited. The Laser
in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient
characteristics, Konstantakopoulou E, Gazzard G, Vickerstaff V, Jiang Y, Nathwani N, Hunter R, Ambler G, Bunce C,
volume 102, pp. 599–603, 2018.72 (continued )
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The results were confirmed in sensitivity analyses (see Appendix 10). Taking into account the outcome data
from all time points across 36 months, the two treatment arms had similar EQ-5D-5L scores at 36 months
[adjusted mean difference 0.02 (95% CI –0.00 to 0.03) and 0.01 (95% CI –0.01 to 0.02), when using exact
times of questionnaire returns).
Secondary outcomes: Glaucoma Utility Index, Glaucoma Symptom Scale and Glaucoma
Quality of Life-15
The average score on the GUI was 0.89 (SD 0.13) in the Laser-1st arm, compared with 0.89 (SD 0.13) in the
Medicine-1st arm (adjusted mean difference 0.007, 95% CI –0.010 to 0.025) (see Table 8 and Figure 5).
The mean GSS score at 36 months was 83.3 (SD 17.3) in the Laser-1st arm, compared with 83.1 (SD 17.7)
in the Medicine-1st arm (adjusted mean difference 1.595, 95% CI –0.797 to 3.988). Mean GQL-15 scores
at 36 months were similar (19.8 in the Laser-1st arm and 19.8 in the Medicine-1st arm, adjusted mean
difference –0.368, 95% CI –0.605 to 1.341). Secondary HRQoL outcomes (GUI, GSS and GQL-15) generally
suggested slightly better HRQoL in the Laser-1st cohort (see Table 8). Repeated-measures analysis showed
worse GSS scores in the Medicine-1st arm at five out of six time points over 36 months.
Pathway clinical effectiveness
At 12 months, 606 eyes (98.9%) were available for analysis in the Medicine-1st arm and 608 eyes (97.8%)
in the Laser-1st arm. At 24 months, 564 eyes (92.0%) were available for analysis in the Medicine-1st arm
and 576 eyes (92.6%) in the Laser-1st arm. At 36 months, 536 eyes (87.7%) of 314 patients in the Laser-1st
arm and 536 eyes (86.2%) of 312 patients in the Medicine-1st arm were available for analysis of clinical
outcomes.
Visual function
Measures of visual function at 36 months are shown in Table 9 for both treatment arms. VA at 36 months was
comparable between the two treatment arms [0.08 (SD 0.17) log of the minimum angle of resolution (logMAR)
for Medicine-1st compared with 0.07 (0.18) for Laser-1st]. In both treatment arms, patients with moderate
and severe OAG showed worse VA than those with OHT and mild OAG [logMAR for the Medicine-1st and
Laser-1st arms, respectively: severe OAG, 0.16 (SD 0.23) and 0.15 (SD 0.18); moderate OAG, 0.12 (SD 0.16)
and 0.11 (SD 0.24); mild OAG, 0.06 (SD 0.15) and 0.08 (SD 0.17); and OHT, 0.08 (SD 0.19) and 0.02 (SD 0.15)].
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FIGURE 5 Mean (a) EQ-5D-5L, (b) GUI, (c) GSS and (d) GQL-15 scores at each time point, across 36 months. Time
point ‘0’ refers to pre-treatment. a, Higher scores on EQ-5D-5L, GUI and GSS indicate better HRQoL; b, higher
scores on GQL-15 indicate worse HRQoL. Adapted by permission from BMJ Publishing Group Limited. The Laser
in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient
characteristics, Konstantakopoulou E, Gazzard G, Vickerstaff V, Jiang Y, Nathwani N, Hunter R, Ambler G, Bunce C,
volume 102, pp. 599–603, 2018.72
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VF MD was also comparable between the two treatment arms at 36 months [–3.21 (SD 3.76) dB for
Medicine-1st compared with –3.19 (SD 3.92) dB for Laser-1st]; VF MD values among those with OHT, as
well as those with mild, moderate or severe OAG, were similar in the two treatment arms. VF pattern SD
was similar between the two treatment arms at 36 months [3.98 (SD 3.29) dB for Medicine-1st, compared
with 3.91 (SD 3.23) dB for Laser-1st]. IOP was reduced from baseline levels for both groups and showed
comparable measures at 36 months across all severity categories [16.3 mmHg (SD 3.9) for Medicine-1st,
compared with 16.6 mmHg (SD 3.6) for Laser-1st] (see Table 9).
Achieving target intraocular pressure
A total of 91% of patients treated with Laser-1st achieved target IOP at the first planned visit, compared
with 89.6% of those treated with Medicine-1st (Table 10). Over 36 months, target IOP was achieved at
93.0% of visits in the Laser-1st arm, compared with 91.3% of visits in the Medicine-1st arm.
At 12 months, 94.7% of eyes (n = 576) in the Laser-1st arm met or were below the target IOP, compared
with 96.2% of the eyes in the Medicine-1st arm (see Table 10). In the first 12 months after treatment,
the proportion of eyes that were consistently at target IOP among patients with OHT or mild or moderate
OAG was higher in the Medicine-1st arm, but, among those with severe OAG, the proportion of eyes
achieving target IOP was similar in both arms (91.3% in the Medicine-1st arm vs. 91.5% in the Laser-1st
arm). This trend was reversed at the end of the second year of the trial, when 96.0% of eyes in the Laser-1st
arm (n = 553) were at target IOP, compared with 94.1% of eyes the Medicine-1st arm (n = 531). Similarly,
more eyes with severe OAG, treated with Medicine-1st, were at target IOP compared with those treated
TABLE 9 Visual acuity, IOP and VF MD and pattern SD at 36 months
Medicine-1st, mean (SD) Laser-1st, mean (SD)
VA (logMAR) at 36 months 0.08 (0.17) 0.07 (0.18)
OHT 0.08 (0.19) 0.02 (0.15)
Mild OAG 0.06 (0.15) 0.08 (0.17)
Moderate OAG 0.12 (0.16) 0.11 (0.24)
Severe OAG 0.16 (0.23) 0.15 (0.18)
VF MD at 36 months –3.21 (3.76) –3.19 (3.92)
OHT –0.94 (1.92) –1.05 (1.98)
Mild OAG –2.14 (1.95) –1.99 (1.93)
Moderate OAG –7.21 (1.92) –7.96 (2.04)
Severe OAG –10.50 (5.01) –10.24 (4.93)
VF pattern SD at 36 months 3.98 (3.29) 3.91 (3.23)
OHT 2.00 (1.19) 2.11 (1.31)
Mild OAG 3.01 (1.94) 2.84 (1.63)
Moderate OAG 7.56 (2.89) 8.40 (3.03)
Severe OAG 10.41 (2.77) 9.63 (2.58)
IOP at 36 months 16.29 (3.87) 16.63 (3.62)
OHT 18.7 (3.73) 18.2 (3.73)
Mild OAG 15.7 (3.45) 16.4 (3.17)
Moderate OAG 14.7 (3.49) 14.4 (3.07)
Severe OAG 15.5 (4.17) 15.5 (4.16)
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with Laser-1st (89.5% vs. 87.5%, respectively). At 36 months, a total of 95% of eyes (n = 509) were at
target IOP in the Laser-1st pathway, compared with 93.1% of eyes (n = 499) in the Medicine-1st pathway.
The proportion of eyes at target IOP among patients with OHT or mild or moderate OAG was higher in the
Laser-1st arm than in the Medicine-1st arm, but, among those with severe OAG, a higher proportion of eyes
treated with Medicine-1st were at target IOP (85.7% in the Medicine-1st arm vs. 84.6% in the Laser-1st
arm). IOP appears to have fluctuated marginally more in the Medicine-1st arm than in the Laser-1st arm
(2.5 mmHg vs. 2.3 mmHg).
Treatment intensity to achieve target intraocular pressure
In the first year after treatment, 85.9% of eyes (n = 522) treated with Laser-1st were at target IOP without
the use of IOP-lowering eyedrops (Table 11). This reduced to 81.6% (n = 470) after the second year and to
78.2% (n = 419) at the end of the trial, at 36 months. In comparison, in the Medicine-1st arm, 82.2% of
eyes (n = 498) were being treated with a single medication at 12 months, falling to 71.5% of eyes (n = 403)
at 24 months and 64.6% of eyes (n = 346) at 36 months. The benefit of not using any eyedrops to control
IOP was lost for 103 eyes in the Laser-1st arm, whereas 152 eyes in the Medicine-1st arm lost the benefit
of a single drop per eye and had to add a second medication to control their IOP.
At the end of the first year, a total of 701 SLT procedures had taken place, with 521 eyes having had a
single SLT and 90 eyes having had two SLTs (see Table 11). During the second year, a further 32 SLTs were
performed for on eyes that had been treated with SLT during the first 12 months. During the third year of
the trial, 35 eyes underwent a second SLT and one eye underwent a third SLT (protocol deviation; see
Appendix 9).
TABLE 10 Control of IOP over 12, 24 and 36 months
Medicine-1st Laser-1st
Eyes achieving target IOP at first planned visit (%)a 89.6 91.0
Proportion of visits at target IOP over 36 months (%) 91.3 93.0
Eyes at target IOP at 12 months, % (n) 96.2 (583) 94.7 (576)
OHT 97.6 (166) 95.3 (183)
Mild OAG 96.4 (320) 95.6 (301)
Moderate OAG 96.5 (55) 90.7 (49)
Severe OAG 91.3 (42) 91.5 (43)
Eyes at target IOP at 24 months, % (n) 94.1 (531) 96.0 (553)
OHT 92.8 (142) 98.3 (171)
Mild OAG 94.5 (294) 95.9 (281)
Moderate OAG 95.3 (61) 95.7 (66)
Severe OAG 89.5 (34) 87.5 (35)
Eyes at target IOP at 36 months, % (n) 93.1 (499) 95.0 (509)
OHT 92.0 (127) 95.6 (151)
Mild OAG 94.6 (261) 96.3 (259)
Moderate OAG 94.5 (69) 96.5 (55)
Severe OAG 85.7 (42) 84.6 (44)
IOP fluctuation over 36 months, mean (SD) 2.5 (1.4) 2.3 (1.0)
a Out of a total of 615 eyes for Medicine-1st and 605 eyes for Laser-1st.
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At the end of the trial, at 36 months, target IOP was achieved without IOP medication in 78.2% of the
eyes (n = 419) treated with Laser-1st (see Table 11); of these, 76.6% (n = 321) had required only one SLT
application. Of the Laser-1st patients, 74.2% (n = 233, 95% CI 69.3% to 78.6%) were eyedrop free at
36 months. A total of 64.6% (n = 346) of the eyes treated with Medicine-1st were being treated with
a single medication at 36 months.
TABLE 11 Intensity of treatment to achieve target IOP
Medicine-1st, n (%) Laser-1st, n (%)
Number of SLT treatments per eye at 12 monthsa 4 701
One SLT treatment 4 521(85.3)
Two SLT treatments 0 90 (14.7)
Three SLT treatmentsb 0 0
Number of medications per eye at target IOP at 12 monthsb
No medication 6 (1.0) 522 (85.9)
One medication 498 (82.2) 49 (8.1)
Two medications 67 (11.1) 4 (0.7)
Three medications 11 (1.8) 1 (0.1)
Four medications 1 (0.2) 0 (0.0)
Number of SLT treatments per eye at 24 monthsa 4 733
One SLT treatment 4 489 (80)
Two SLT treatments 0 122 (20)
Three SLT treatmentsb 0 0
Number of medications per eye at target IOP at 24 monthsb
No medication 14 (2.5) 470 (81.6)
One medication 403 (71.5) 73 (12.7)
Two medications 94 (16.7) 8 (1.4)
Three medications 18 (3.2) 2 (0.3)
Four medications 2 (0.4) 0 (0.0)
Number of SLT treatments per eye at 36 monthsa 6a 770
One SLT treatment 6 453 (74.0)
Two SLT treatments 0 157 (26.0)
Three SLT treatmentsb 0 1 (0.2)
Number of medications per eye at target IOP at 36 monthsb
No medication 16 (3.0) 419 (78.2)
One medication 346 (64.6) 64 (12.0)
Two medications 99 (18.5) 21 (3.9)
Three medications 35 (6.5) 4 (0.8)
Four medications 3 (0.6) 1 (0.2)
a Includes eyes that were not at target IOP.
b includes eyes that had undergone trabeculectomy.
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Control of disease
More treatment escalations took place in the Medicine-1st arm (n = 348) than in the Laser-1st arm
(n = 299). Thirty-six eyes in the Medicine-1st arm showed algorithm-confirmed disease deterioration
(three eyes converted from OHT to OAG and in 33 eyes OAG progressed), compared with 23 eyes in the
Laser-1st arm (two eyes showed OHT conversion to OAG and in 21 eyes OAG worsened) (Table 12).
Over the 36-month duration of the trial, target IOP was revised in 38 eyes, in 33 patients, in the Medicine-1st
arm (total 38 IOP revisions) and in 38 eyes, in 37 patients, in the Laser-1st arm (total 41 IOP revisions)
(see Table 12). IOP was revised downwards in 31 eyes (16 in the Medicine-1st arm and 15 in the Laser-1st arm)
because of objective signs of disease deterioration/progression despite the IOP target being met. The vast
majority of the downward revisions of target IOP (28 out of 31) were for eyes with OAG. Additionally,
in 48 cases (22 in the Medicine-1st arm and 26 in the Laser-1st arm), the IOP target was revised upwards,
despite the initial IOP target not having been met repeatedly, because there was no evidence of disease
deterioration/progression. There were proportionally more upwards target IOP revisions in eyes with mild
OAG (8 out of 22 in the Medicine-1st arm and 14 out of 26 in the Laser-1st arm). Eleven eyes (1.8%)
required IOP-lowering surgery (trabeculectomy) in the Medicine-1st arm, compared with none in the
Laser-1st arm.
TABLE 12 Treatment escalations, disease progression, IOP target revisions and glaucoma surgeries, describing
overall control of the disease
Medicine-1st Laser-1st
Treatment escalations over 36 months (n)a 348 299
Disease progression during the trial, % (n) 5.8 (36) 3.8 (23)
From OHT to OAG (n)b 3 2
OAG progression (n) 33 21
Algorithm defined VF progression 27 18
Algorithm defined optic disc progression 3 2
Algorithm-defined VF and disc progression 3 1
IOP target revisions 38 (38 eyes, 33 patients) 41 (38 eyes, 37 patients)
Upwards IOP revisions over 36 months (n) 22 26
OHT 4 5
Mild OAG 8 14
Moderate OAG 7 1
Severe OAG 3 6
Downwards IOP revisions over 36 months (n) 16 15
OHT 1 2
Mild OAG 5 5
Moderate OAG 6 5
Severe OAG 4 3
Glaucoma surgeries (n)
Trabeculectomy 11 0
Trabeculectomy revision 7 (5 eyes) 0
a Treatment escalations initiated by the algorithm and the clinicians.
b Conversion of OHT to OAG required a DSS-derived sign of progression and verification by a consultant ophthalmologist.
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Safety profile
Adverse events
A total of 1196 AEs were reported for the Medicine-1st arm, compared with 900 in the Laser-1st arm,
although the number of patients reporting at least one AE was balanced (260 patients in the Medicine-1st
arm vs. 261 in the Laser-1st arm) (Table 13). On average, four AEs were reported per patient treated with
Medicine-1st compared with three AEs per patient treated with Laser-1st.
TABLE 13 Adverse events
Summary Medicine-1st Laser-1st Total
Total number of AEs 1196 900 2096
Number of patients reporting at least
one AE
260 261 521
Number of AEs reported per person,
mediana (IQR)
4 (2–8) 3 (1–5) 3 (2–7)
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Systemic AEs/symptoms 298 115 (31.8) 236 98 (27.6) 534 213 (29.7)
Pulmonary problems 23 14 (3.9) 24 12 (3.4) 47 26 (3.6)
Cardiac events 6 5 (1.4) 8 5 (1.4) 14 10 (1.4)
Heart block 1 1 (0.3) 0 0 (0) 1 1 (0.0)
Cardiac arrhythmia 5 4 (1.1) 8 5 (1.4) 13 9 (1.3)
Drug-related events 148 52 (14.4) 87 23 (6.5) 235 75 (10.5)
Impotence 10 3 (0.8) 7 4 (1.1) 17 7 (1.0)
Depression 18 9 (2.5) 14 4 (1.1) 32 13 (1.8)
Somnolence/tiredness 60 31 (8.6) 34 17 (4.8) 94 48 (6.7)
Nightmares 21 11 (3.0) 15 4 (1.1) 36 15 (2.1)
Generalised skin rash 18 11 (3.0) 13 8 (2.3) 31 19 (2.6)
Taste disturbance 21 18 (5.0) 4 3 (0.8) 25 21 (2.9)
Otherb 121 82 (22.7) 117 78 (22.0) 238 160 (22.3)
Ophthalmic AEs 809 241 (66.6) 492 188 (53.0) 1388 429 (59.8)
Aesthetic eyedrop side effects 117 56 (15.5) 12 7 (2.0) 129 63 (8.8)
Change in iris colour 6 4 (1.1) 1 1 (0.3) 7 5 (0.7)
Periocular pigmentation 24 16 (4.4) 4 4 (1.1) 28 20 (2.8)
Excessive lash growth 87 48 (13.3) 7 5 (1.4) 94 53 (7.4)
Ophthalmic allergic reactions 33 17 (4.7) 18 13 (3.7) 51 30 (4.2)
Periocular skin rash 16 10 (2.8) 5 5 (1.4) 21 15 (2.1)
Allergy 17 11 (3.0) 13 8 (2.3) 30 19 (2.6)
Uveitis 1 1 (0.3) 2 2 (0.6) 3 3 (0.4)
Reactivation of herpes 1 1 (0.3) 1 1 (0.3) 2 2 (0.3)
Otherc 744 118 (32.6) 459 117 (33.0) 1041 235 (32.8)
continued
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Overall, systemic AEs were similar between the two treatment arms (see Table 13): 26 cardiac AEs in the
Medicine-1st arm vs. 28 in the Laser-1st arm and six pulmonary systemic AEs in the Medicine-1st arm vs.
eight in the Laser-1st arm. Eyedrop-related systemic AEs (impotence, depression, somnolence/tiredness,
taste disturbance, skin rash and nightmares) were reported more often and by more patients in the
Medicine-1st arm [148 events reported by 52 patients (14.4%)] than in the Laser-1st arm [87 events
reported by 23 patients (6.5%)].
There were more ophthalmic eyedrop-related AEs reported by patients in the Medicine-1st arm (150
aesthetic side effects and topical allergic reactions reported by 73 patients) than reported by patients in
the Laser-1st arm (30 events reported by 20 patients). There were a total of 80 treatment changes (not
escalations) attributable to eyedrop side effects or intolerances during the course of the trial; 69 changes
to treatment were applied to 59 eyes in 41 patients (11.3% of patients) treated with Medicine-1st and 11
changes to treatment were applied to seven eyes in four patients (1.1% of patients) treated with Laser-1st.
Transient discomfort, blurred vision, photophobia and hyperaemia after the SLT treatment were reported
by 34.4% (n = 122) of the patients in the Laser-1st arm and were of a transient nature. AEs (including
variations in the number of laser shots, visualisation of angle, breaks taken and discomfort) were reported
for 14 patients during the SLT procedure.
There were no sight-threatening complications of SLT (see Table 13). Cases of reactivation of herpes
simplex keratitis (one in each treatment arm) and uveitis (two in the Laser-1st arm and one in the
Medicine-1st arm) were comparable in the two treatment arms. In only six eyes in six patients was a
post-SLT IOP rise noted (> 5 mmHg), identified on the day of laser treatment. Only one of these eyes
required treatment. There were no peripheral anterior synechiae.
Serious adverse events
Overall, serious adverse events were balanced between the two treatment arms (Table 14); there were
97 events in the Medicine-1st arm, reported by 69 patients, and 107 events in the Laser-1st arm, reported
by 64 patients. The most common ocular SAEs were vascular occlusions, retinal detachments, choroidal
neovascularisation and angle closure. In terms of systemic SAEs, pulmonary problems requiring hospitalisations
were balanced between the Medicine-1st and the Laser-1st arms (three and two, respectively), as were cardiac
events (seven and nine, respectively). There were few and balanced cerebrovascular accidents (one in the
Medicine-1st arm and with two in the Laser-1st arm). There were more cancer diagnoses (n = 15) and deaths
(n = 8) in the Laser-1st arm than in the Medicine-1st arm (nine and two events, respectively).
TABLE 13 Adverse events (continued )
Summary Medicine-1st Laser-1st Total
Laser-related AEs 2 1 (0.3) 172 122 (34.4) 180 123 (17.2)
IOP spike post SLTd 0 0 6 6 (1.7) 6 6 (0.8)
Inflammation 0 0 (0) 1 1 (0.3) 1 1 (0.1)
Discomfort 1 1 (0.3) 92 82 (23.1) 93 83 (11.6)
Blurred vision 0 0 (0) 23 21 (5.9) 23 21 (2.9)
Change in refraction 0 0 (0) 5 4 (1.1) 5 4 (0.6)
Otherc 1 1 (0.3) 51 47 (13.2) 52 48 (6.7)
a Of those with at least one AE.
b Includes ocular irritation, discomfort, dry eye, unspecified retinal haemorrhages, vision changes, flashes, floaters,
conjunctivitis, blepharitis, vascular occlusions, diabetic retinopathy and macular pathology.
c See Appendix 11.
d IOP spike defined as > 5mmHg; only one eye received treatment.
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Ocular comorbidities and cataract
Ocular comorbidities developing during the course of the trial are shown in Table 15. Overall, these were
balanced between the two arms and not related to the treatment. Twenty-five cataract extractions were
carried out in 17 patients treated in the Medicine-1st arm and 13 cataract extractions were carried out in
11 patients treated in the Laser-1st arm.
Concordance/compliance
At baseline, concordance with treatment was lower among patients who were to be treated with Medicine-
1st than among those allocated to treatment with Laser-1st (the proportion taking their eyedrops correctly was
75% vs. 92.5%, respectively). By the end of the trial, at 36 months, self-reported concordance had improved
and was similar between the two treatment arms (99% of eyedrops used correctly) (Tables 16 and 17).
TABLE 14 Serious adverse events
Medicine-1st Laser-1st Total
Total number of events 97 107 204
Total number of patients reporting 69 64 133
Events, n n (%) Events, n n (%) Events, n n (%)
Ocular 9 6 (1.7) 10 8 (2.2) 17 14 (1.9)
CRVO/BRVO 1 1 1 1 2 2
Retinal detachment 1 1 3 2 4 3
Anterior chamber surgery 1 1 0 0 1 1
Posterior segment surgery 1 1 0 0 1 1
Corneal ulcer 1 1 0 0 1 1
CNV 2 2 3 3 5 5
Angle closure requiring intervention 2 1 2 1 4 2
Post-traumatic uveitis 0 0 1 1 1 1
Pulmonary problemsa 3 3 (0.8) 2 2 (0.5) 5 5 (0.7)
Cerebrovascular accidents 1 1 (0.3) 2 2 (0.5) 3 3 (0.4)
Cardiac eventsa 7 7 (1.9) 9 8 (2.2) 16 15 (2.1)
Cancer 9 8 (2.2) 15 13 (3.6) 24 21 (2.9)
Death 2 2 (0.5) 8 8 (2.2) 10 10 (1.4)
Other systemic 66 50 (15.3) 61 43 (12.1) 127 93 (13)
BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion.
a Requiring hospitalisation.
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TABLE 15 Ocular comorbidities developed during the trial and cataract surgeries
Medicine-1st (n) Laser-1st (n) Total (N)
Events
Patients
reporting Events
Patients
reporting Events
Patients
reporting
Ocular comorbidities 12 16 28 22
Central retinal artery
occlusion
3 2 1 1 4 3
Branch retinal artery
occlusion
1 1 2 1 3 2
Diabetic retinopathy 0 0 1 1 1 1
Diabetic macular oedema 0 0 3 2 3 2
Retinal detachment/tear 1 1 3 2 4 3
Anterior chamber surgery 1 1 0 0 1 1
Posterior segment surgerya 1 1 0 0 1 1
Corneal ulcer 1 1 0 0 1 1
CNV 2 2 3 3 5 5
Angle closure requiring
interventionb
2 1 2 1 4 2
Post-traumatic uveitis 0 0 1 1 1 1
Cataract surgeries 25 17 13 11 38 28
CNV, choroidal neovascularisation.
a Not related to retinal detachment.
b One patient in the Medicine-1st arm underwent phacoemulsification in both eyes and one patient in the Laser-1st arm
received laser peripheral iridotomy in both eyes.
Note
Some of the above comorbidities were reported as AEs, some as SAEs and are included in the relevant tables.
TABLE 16 Responses of patients treated with Laser-1st regarding the use of their eyedrops
Follow-up time point (months)
Baseline 6 12 18 24 30 36
What percentage of your eyedrops do you think you took correctly (in past month)?
Total responses (n) 10 41 49 61 62 65 77
Median (IQR) 92.5
(75–100)
99
(90–100)
98
(90–75)
99
(80–100)
99
(85–100)
99
(90–100)
99
(90–100)
I’m the sort of person who follows doctors’ orders exactly
Total responses (n) 351 324 311 299 300 286 299
Strongly agree, n (%) 266 (75.8) 245 (75.6) 226 (72.7) 212 (70.9) 209 (69.7) 203 (71.0) 210 (70.2)
Somewhat agree, n (%) 77 (21.9) 70 (21.6) 74 (23.8) 73 (24.4) 80 (26.7) 74 (25.9) 79 (26.4)
Neither agree nor
disagree, n (%)
7 (2.0) 5 (1.5) 8 (2.6) 10 (3.3) 6 (2.0) 4 (1.4) 7 (2.3)
Somewhat disagree, n (%) 0 (0) 1 (0.3) 3 (1) 2 (0.7) 4 (1.3) 5 (1.8) 2 (0.7)
Strongly disagree, n (%) 1 (0.3) 3 (0.9) 0 (0) 2 (0.7) 1 (0.3) 0 (0) 1 (0.3)
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Cost-effectiveness
Throughout the 36 months of the trial, patients treated with Medicine-1st made 2907 ophthalmology
outpatient visits and patients treated with Laser-1st made 3441 visits. The latter includes visits at 2 weeks
after the SLT treatment, which served as a safety check. None of these visits revealed a pathology that
changed the course of management. A detailed table summarising all of the medical contacts is shown in
Appendix 12 (see Table 28).
Quality-adjusted life-years
Descriptive statistics for the EQ-5D-5L are reported in Table 8. In the complete-case analysis, the Laser-1st
arm had a mean of 2.63 adjusted and discounted QALYs across 3 years (n = 261, 95% CI 2.60 to 2.66),
with 2.61 QALYs in the Medicine-1st arm (n = 263, 95% CI 2.57 to 2.64) with an adjusted difference of
0.025 (95% CI –0.020 to 0.070; p = 0.277). In the multiple imputation analysis, there was an adjusted
difference of 0.014 [standard error (SE) 0.220, 95% CI –0.029 to 0.057; p = 0.526].
Cost of selective laser trabeculoplasty
There were a range of different models for delivering SLT across the different sites. Although all sites had a
dedicated laser session, this was usually attended by a mixture of patients, some receiving other types of
laser treatment. The procedure was performed by ophthalmologists of a range of grades, covering registrar
through to consultant. Supporting staff may have been a health-care assistant or a lower-grade nurse.
Sessions tended to last 4 hours, with sites treating between five and eight patients at each session.
Depending on the number of sessions, sites may treat between 350 and 200 patients a year with the laser
(the laser can be used for procedures other than just SLT).
At a cost of £38,995 for the machine, and an annual maintenance cost of £6395, the cost per patient
for the machine, annuitising for a 10-year lifespan, is £32 per patient if one assumes that each site sees
300 patients per year (Lumenis, 2018, personal communication). Alternatively, the per patient cost is £55 if
one assumes that each site sees 200 patients per year. If it is assumed that the procedure is carried out by a
consultant, takes 30 minutes and there is a mixed model of care between nurses and health-care assistants
(half and half), the total staff cost is £64 per patient . If the procedure takes 45 minutes, it is £97 per
patient, using the same mix of staff (overheads and oncosts are included in the salary costs).
TABLE 17 Responses of patients treated with Medicine-1st, regarding the use of their eyedrops
Follow-up time point (months)
Baseline 6 12 18 24 30 36
What percentage of your eyedrops do you think you took correctly (in past month)?
Total responses (n) 11 319 298 289 290 284 286
Median (IQR) 75
(25–100)
99
(90–100)
99
(90–100)
99
(95–100)
99
(90–100)
99
(93–100)
99
(90–100)
I’m the sort of person who follows doctors’ orders exactly
n 354 324 305 302 290 293 294
Strongly agree, n (%) 249 (70.3) 247 (76.2) 226 (74.1) 221 (73.2) 211 (72.8) 219 (74.7) 211 (71.8)
Somewhat agree, n (%) 82 (23.2) 73 (22.5) 73 (23.9) 73 (24.2) 75 (25.9) 68 (23.2) 78 (26.5)
Neither agree nor
disagree, n (%)
16 (4.5) 1 (0.3) 5 (1.6) 5 (1.7) 2 (0.7) 4 (1.4) 3 (1)
Somewhat disagree, n (%) 5 (1.4) 2 (0.6) 1 (0.3) 2 (0.7) 1 (0.3) 2 (0.7) 1 (0.3)
Strongly disagree, n (%) 2 (0.6) 1 (0.3) 0 (0) 1 (0.3) 1 (0.3) 0 (0) 1 (0.3)
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As a result, the total cost of a SLT is likely to be between £96 and £151 depending on the assumptions
made. We have used the upper estimate of £151 as the cost per patient for a SLT to use the more
conservative estimate. Descriptive statistics for SLTs are reported in Table 11. The average total cost per
patient for SLT is reported in Table 18.
Ocular-related costs
Descriptive statistics for eyedrops, surgery and IOP appointments are reported in Table 11. Total
ophthalmology costs collected from patient files are reported in Tables 11 and 18. Patients randomised to
Laser-1st had significantly higher costs for SLT and scheduled ophthalmology checks (excluding the 2-week
IOP check). Patients randomised to Medicine-1st had significantly higher costs for eyedrops, ocular surgery
(including preoperative assessment) and IOP checks. The ophthalmology-related costs in the Medicine-1st
arm were £451 (95% CI –£580 to –£322) higher in the unadjusted analysis and £447 (95% CI –£573 to
–£322) higher in the adjusted analysis with bootstrapped bias-corrected CIs. There were no significant
differences between the two groups in community eye-related costs collected using the CSRI (Table 19).
Other health-care resource use
There were no significant differences between the two arms in health-care costs collected using the CSRI
(Table 20), with a difference of –£319 (95% –£757 to £118) for the adjusted analysis with 95% bias-
corrected bootstrapped CIs. If missing data are imputed using chained equations, then the adjusted
discounted difference is £36 (95% CI –£366 to £437).
Inpatient costs have been calculated separately, given that information on inpatient stays could be
supplemented with SAE data. The mean inpatient cost over 3 years (discounted) for patients randomised
to Medicine-1st is £799 (SD £2592), with a mean cost of £1095 (SD £3252) for patients randomised to
Laser-1st and an adjusted difference of £336 (95% CI –£97 to £770), with CIs calculated from bias-
corrected bootstrap.
TABLE 18 Total average cost per patient of ophthalmology-related appointments taken from patient files over
3 years (unadjusted)
Cost component
Medicine-1st (n= 362),
mean (SD)
Laser-1st (n= 356),
mean (SD)
Difference,
mean (95% CI)
SLT 3 (22) 208 (82) 205 (196 to 213)
Eyedrops 526 (202) 61 (144) –465 (–491 to –440)
Ocular surgery 242 (709) 109 (386) –134 (–218 to –50)
Preoperative assessment 17 (50) 8 (32) –9 (–15 to –3)
Postoperative assessment 1 (14) 0.3 (5) –0.5 (–2 to 1)
IOP checksa 170 (290) 34 (111) –135 (–168 to –103)
Scheduled checks 446 (144) 535 (150) 90 (68 to 111)
Unscheduled checks 26 (86) 21 (57) –5 (–16 to 5)
3-year check 63 (42) 67 (40) 4 (–2 to 10)
Total 1495 (1083) 1044 (608) –451 (–580 to –322)
a Excluding 2-week IOP check.
Note
Costs are in 2016/17 Great British pounds.
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Total health and social care costs
Total costs include the cost of SLTs, eyedrops, eye-related costs and non-eye-related health and social care
costs. Including all costs with no imputation, the total adjusted cost for patients randomised to Medicine-1st
over 3 years, discounted, is £3993 (SE £215, 95% CI £3571 to £4414) and for Laser-1st it is £3890
(SE £245, 95% CI £3409 to £4371), with a difference of –£103 (SE £325, 95% CI –£739 to £534; p = 0.752).
Including imputed missing community data, the difference in costs is –£105 (SE £348, 95% CI –£788 to
£579; p = 0.764).
Incremental cost-effectiveness ratio and cost-effectiveness acceptability curve
For ophthalmology and total costs, Laser-1st dominates Medicine-1st in that it results in more QALYs for
a lower cost. For ophthalmology-only costs, the results of the multiple imputation (QALYs imputed only)
and bootstrap, accounting for correlation between costs and QALYs using seemingly unrelated regression,
are that Laser-1st results in an average cost saving of –£458 per patient, with 95% of iterations falling
between –£585 and –£345, and 0.014 additional QALYs, with 95% of bootstrap replications falling
TABLE 19 Eye-related costs taken from completed CSRI over 3 years (discounted and unadjusted)
Cost component
Medicine-1st, mean (SD) Laser 1st, mean (SD)
Difference,
mean (95% CI)
Baseline
(n= 354)
3 years
(n= 223)
Baseline
(n= 348)
3 years
(n= 217)
Optometrist 49 (37) 125 (95) 47 (39) 139 (111) 14 (–7 to 35)
Community costsa (eye related) 7 (16) 23 (43) 7 (16) 19 (50) –4 (–12 to 5)
Total (£) 56 (43) 133 (109) 54 (45) 141 (130) 8 (–14 to 30)
a Community costs include general practitioner, primary care nurse and social care.
Notes
Costs are in 2016/17 Great British pounds.
Baseline values are 6 months prior to randomisation.
TABLE 20 Costs collected using the CSRI for non-eye-related health-care resource use over 3 years (discounted and
unadjusted)
Cost component
Medicine-1st, mean (SD) Laser-1st, mean (SD)
Difference,
mean (95% CI)
Baseline
(n= 354)
3 years
(n= 224)
Baseline
(n= 348)
3 years
(n= 231)
General practitionera 47 (65) 138 (171) 48 (79) 133 (133) –5 (–36 to 26)
Social care 4 (40) 27 (109) 2 (15) 26 (134) –1 (–25 to 22)
A&E attendances 9 (40) 60 (163) 13 (51) 51 (147) –9 (–39 to 22)
Acute outpatientb 115 (182) 525 (683) 97 (172) 436 (706) –89 (–227 to 49)
Day cases 256 (610) 1184 (2071) 230 (602) 920 (1577) –264 (–619 to 90)
Total (£) 425 (712) 1776 (2538) 386 (719) 1389 (2100) –387 (–815 to 41)
A&E, accident and emergency.
a Including practice nurse.
b Excludes eye-related costs.
Notes
Costs are in 2016/17 Great British pounds.
Baseline values are 6 months prior to randomisation.
Inpatient data includes SAE costs.
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between –0.018 and 0.046. If non-eye-related costs are also included, the average cost saving of Laser-1st
is –£126 per patient, with 95% of bootstrap replications falling between –£796 and £487.
The CEAC is presented in Figure 6. If ophthalmology-only costs are included, at a £20,000 and £30,000
willingness to pay for a QALY, there is a 97% and 93% probability, respectively, that Laser-1st is cost-
effective compared with Medicine-1st over 3 years, discounted and adjusted. For all health-care-related
costs, including non-eye-related costs, at both a £20,000 and a £30,000 willingness to pay for a QALY,
there is a 68% chance that Laser 1st is cost-effective compared with Medicine-1st, discounted and
adjusted, over 3 years.
Sensitivity analysis
l If the SLT cost was at the lower end of the microcosting estimate, Laser-1st would result in a £176 cost
saving compared with eyedrops for all health-care costs. The cost of a SLT based on NHS reference
costs90 is £188. If this value is used, Laser-1st results in £89 in cost savings if all health-care costs
are included.
l The average cost of the 2-week check following SLT in the Laser-1st arm was £128 and £20 in the
Medicine-1st arm, with the 2-week check costing an additional £108 for patients randomised to
Laser-1st. If the 2-week check is included in the analysis, Laser-1st results in £18 of cost savings if all
health-care costs are included.
l In the complete-case analysis, the Laser-1st arm results in a mean of 2.63 adjusted and discounted
QALYs over 3 years (n = 261, 95% CI 2.60 to 2.65), with 2.61 QALYs in the Medicine-1st arm (n = 263,
95% CI 2.57 to 2.62) and an adjusted difference of 0.032 (95% CI –0.003 to 0.068; p = 0.075).
Laser-1st dominates Medicine-1st, with lower costs and more QALYs.
Protocol deviations and violations
A list of protocol deviations and violations is shown in Appendix 9.
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FIGURE 6 Cost-effectiveness acceptability curve of Laser-1st compared with Medicine-1st based on bootstrapped,
imputed, discounted and adjusted data: ophthalmology costs and all health-care costs. Reproduced from Gazzard
et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
(http://creativecommons.org/licenses/by/4.0/).
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Chapter 4 Health economic decision model
Introduction
We collected costs and monitored QoL over the 3-year time horizon of the trial. However, it is possible that
further costs and benefits will accrue beyond the time horizon of the trial.
Aim
The aim of the economic evaluation was to calculate the mean incremental cost per QALY of Laser-1st
compared with Medicine-1st for the lifetime of the patient. Health service costs and QALYs were calculated
for the lifetime of patients, drawing on data from the trial and the literature where appropriate.
Methods
Design
In the lifetime model, cost-effectiveness was calculated in terms of the incremental cost per QALY of
Laser-1st compared with Medicine-1st. The model was developed and populated based on available
evidence, including the data collected during the trial. Based on previously identified models73 and expert
clinical input, the proposed design is a Markov state-transition model that allows movement between
glaucoma states. Values for the model have predominantly been taken from data collected from the trial.
A systematic search of the literature was also conducted to ratify the evidence from the trial with that in
the wider literature. Estimates for mortality have been derived from national data sets.75
The model has cycles of 6 months’ duration and calculates expected costs and outcomes for a hypothetical
cohort of patients with the same age, sex, ethnicity and deprivation composition as patients enrolled in
the LiGHT trial. The number of cycles was determined by the number of years between the first cycle and
when all patients in the model had died. Costs and QALYs have been discounted at 3.5% per year, in line
with NICE guidelines.76 The health states in the model were OHT, mild glaucoma, moderate glaucoma,
severe glaucoma and death. Health states were defined with associated costs and utility values.
Transition probabilities were obtained from the LiGHT trial findings for the first 3 years of the model and a
combination of published studies and LiGHT trial findings for the remaining years of the analysis. Given the
duration of follow-up in the trial, health status utility and annual costs associated with each Markov state
were based on within-trial data; mean utilities and costs for each state were calculated based on the
patient-level data in the 3-year follow-up period in the study. These values were utilised in the long-run
model. The within-trial values were also compared and supplemented with data from published studies
(see Traverso et al.77), if appropriate. We undertook deterministic (one-way, two-way, multiway) analyses
and a probabilistic sensitivity analysis (PSA), the latter assuming appropriate distributions and parameter
values.79 The values from the PSA were used to construct a CEAC, which shows the probability that Laser-1st
is cost-effective compared with Medicine-1st over the full lifetime of patients for a range of values of the
NHS’s willingness to pay for an additional QALY.
The costs of the treatment pathway were also estimated using a Markov model that estimated the cost of
eyedrops, surgery and SLT and the costs for patients who were ‘drops free’. This model was run in conjunction
with the aforementioned model and the results were combined.
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Markov model structure
The model structure is presented in Figure 1. Generally speaking, OAG is a non-reversible condition,
which is reflected in the model structure, in which it was not possible for patients to return to a less severe
glaucoma state at the end of each cycle. However, in reality, it is expected that a number of patients will
break this assumption as a result of fluctuation within patients, measurement error and other procedures
(e.g. cataract surgery), rather than true improvement. Only two patients in the trial were at a better state
at 36 months than at baseline (both in the medication arm). These patients were removed from the
analysis, assuming measurement error.
Patients in both arms progressed through health states until the entire cohort entered the ‘death’ state.
The rate of progression was calculated based on patients severity at the 36-month follow-up compared
with baseline. Cycle-specific transition probability was calculated using the method and formula set out in
Briggs et al.79 of r = –[ln(1 – P)]/t and transition probability = 1 – exp(–rt), where r is the rate, P is the
probability of an event and t is time.
The model was developed in Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA).
Costing of the treatment pathway
The second and third Markov models were developed to capture treatment costs, including the costs of
eyedrops, surgery and SLT. The model structures for each pathway are shown in Figures 7 and 8. The costs
estimated in the model were combined with the health state costs in the disease state model (Figure 9).
The cost of eyedrops depended on whether the patient was receiving first, second, third or fourth
escalation treatment. The model allowed for patients to remain in each eyedrops subcategory after each
cycle or progress to the next treatment escalation. Patients could stay in the surgery state for only one
cycle, following which they moved into the eyedrops-free window. Patients could also remain in the
eyedrops-free state for multiple cycles.
The Laser-1st pathway included a state for patients who received SLT and allowed a number of patients to
undergo a second laser treatment, although this transition could be made only once, in line with the trial
protocol.
Eyedrops: fourth
escalation+
Eyedrops: third
escalation
Eyedrops: second
escalation
Eyedrops: first
escalation
Surgery
Eyedrops
free
Diagnosis
FIGURE 7 Medicine-1st treatment pathway.
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FIGURE 8 Laser-1st treatment pathway.
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FIGURE 9 Markov model structure.
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Eyedrops treatment
The cost of eyedrops was calculated as the average for patients who received their first, second, third and
fourth escalation of treatment by eyedrops. The fourth escalation group was inclusive of subsequent lines
of medical therapy.
Time-to-eyedrops analysis
The proportion of people moving into each of the eyedrops escalations was based on the number of changes
made to patients’ eyedrops medication over the 3 years of the trial by trial arm. The same methodology for
calculating cycle-specific transition probabilities, as described in Markov model structure, was used.
Time-to-surgery analysis
We conducted a survival analysis with Weibull distribution to calculate the probability of surgery in each
cycle by trial arm. The Weibull model was calculated and applied in the model using the methodology in
Briggs et al.,79 to extrapolate beyond the time horizon of the trial.
Literature search
A literature search was undertaken to identify previous economic evaluations with modelling components
in OHT and glaucoma, and epidemiological studies of utility scores, costs or disease progression in OHT
and glaucoma. We searched the following databases: York Centre for Reviews and Dissemination
database, cost-effectiveness registry, The Cochrane Library and MEDLINE. Search terms relating to costs,
utility tariffs, QALYs and glaucoma were used.
Population
Patients with a diagnosis of OAG or OHT with a decision to treat made by a consultant glaucoma
specialist. The age, sex, ethnicity and socioeconomic deprivation of patients was assumed to be the same
as the patients enrolled in the LiGHT trial.
Intervention and comparator
Intervention
Initial treatment with SLT: Laser-1st.
Comparator
Current standard initial treatment with topical medication alone: Medicine-1st.
Perspective
Costs were from the perspectives of NHS England and Personal and Social Services (PSS).
Time horizon
The time horizon for the model was the lifetime (maximum 30 years) for a hypothetical cohort of patients
distributed across age bands in line with the trial population. All costs and QALYs were discounted by
3.5%, in line with NICE guidance.76
Cycle length
The cycle length in the model was 6 months. The cycle length specifies the time interval at which the
cohort can change health state.
Health states
Health states in the model were used to allocate costs and consequences as a result of various events.
Events within a state were assumed to happen at the start of the 6-month cycle and, hence, costs and
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consequences for the period were calculated from the first time that the patient entered a state. There
were five health states in the model as follows:
1. OHT
2. glaucoma ‘mild’
3. glaucoma ‘moderate’
4. glaucoma ‘severe’
5. death.
The health states in the model are displayed in Figure 1. The mild, moderate and severe glaucoma health
states and OHT were defined in accordance with the structured protocols applied (see Table 1). The
definitions were based on the Canadian IOP guidelines.69 The definition of health states from any costs and
QALYs assigned from the literature was carefully compared with the health state definitions used in the
trial for suitability. In particular, the ‘severe’ state as defined in the trial was likely to be less severe than in
other trials because of the nature of the recruitment selection process, as a result of which patients with
more severe disease were not considered suitable for the study.
Death was an absorbing state in the model, meaning that any individual can move into this state from any
other state within the model. Once a patient entered the death state in the model, no costs or utilities
were applied.
Costs
Individual costs included in the model were as follows:
l Cost of SLT: the mean cost per patient of SLT in the Laser-1st arm was £151 per SLT based on the
figure reported in the trial-based health economic evaluation (see Cost-effectiveness analysis).
l Cost of trabeculectomy: the cost of trabeculectomy was taken from NHS reference costs 2016/1790 and
as a day-case cost.
l Cost of eyedrops: the cost of eyedrops was calculated using trial data and the average cost per patient
at each eyedrop change.
l Health state costs: health-care costs were calculated as the average 36 months’ health and social costs
for patients with OHT or one of the three OAG health states at 36 months and by trial arm. They
included all costs, excluding SLT, eyedrops and surgery (trabeculectomy). They included the cost of
ophthalmology appointments, including IOP checks.
Quality-adjusted life-years
Quality-adjusted life-years for each health state were calculated based on patients’ OHT and OAG severity
at 35 months and the mean GUI61 for those patients by trial arm. Utility values collected using the EQ-5D-5L
were applied in the sensitivity analysis.
Cost-effectiveness analysis
We calculated the total costs and QALYs for patients with OAG and OHT treated by Laser-1st compared
with Medicine-1st.
The ICER was calculated as the ratio of the difference in total cost for a patient over a lifetime for the
intervention and the comparator, and the difference in total QALYs for a patient over a lifetime for the
treatment and the comparator:79
ICER = (Total costintervention – Total costcomparator) / (QALYintervention – QALYcomparator). (1)
All future benefits (QALYs) and costs were discounted in line with NICE guidance76 to capture time
preferences for costs and benefits.
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Sensitivity analysis
We undertook deterministic (one-way, two-way and multiway) analyses and a PSA, the latter assuming
appropriate distributions and parameter values.79 The values from the PSA were used to construct a CEAC,
which showed a probability that Laser 1st is cost-effective compared with Medicine-1st over the full
lifetime of patients, for a range of values of the NHS’s willingness to pay for an additional QALY.
Probabilistic sensitivity analysis and cost-effectiveness acceptability curve
We conducted a full PSA to generate a CEAC and calculate the probability that a given option was
cost-effective compared with a range of prestated comparators based on 1000 iterations of the model.
All values in the model were assigned appropriate distributions and parameter values.79
Deterministic
We varied input variables, either individually or in combination, whereas other variables are held at their
baseline value.
Results
Inputs for model
The inputs for the model are reported in Table 21. There was a significant reduction in the rate of surgery
in the Laser-1st arm compared with the Medicine-1st arm (hazard ratio 0.156, 95% CI 0.046 to 0.527).
TABLE 21 Inputs for model: 1-year values
Variable Mean SE Distribution Source
Age at time 0 63
Patients OHT at time 0 (%) 30
Patients mild at time 0 (%) 49
Patients moderate at time 0 (%) 15
Patients severe at time 0 (%) 6
Transition probabilities variables (1 year)
Laser-1st
OHT to mild 0.07 0.04 Beta
OHT to moderate 0.04 0.04 Beta
OHT to severe 0.02 0.02 Beta
Mild to moderate 0.08 0.04 Beta
Mild to severe 0.04 0.03 Beta
Moderate to severe 0.22 0.12 Beta
Second SLT 0.10 0.03 Beta
Medicine free to first-line medicine 0.07 0.02 Beta
First- to second-line medicine 0.17 0.06 Beta
Second- to third-line medicine 0.05 0.04 Beta
Third- to fourth-line medicine 0.01 0.02 Beta
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TABLE 21 Inputs for model: 1-year values (continued )
Variable Mean SE Distribution Source
Medicine-1st
1-year probability of OHT to mild 0.10 0.05 Beta
1-year probability of OHT to moderate 0.03 0.03 Beta
1-year probability of OHT to severe 0.01 0.02 Beta
1-year probability of mild to moderate 0.07 0.04 Beta
1-year probability of mild to severe 0.06 0.03 Beta
1-year probability of moderate to severe 0.17 0.13 Beta
First- to second-line medicine 0.15 0.03 Beta
Second- to third-line medicine 0.07 0.02 Beta
Third- to fourth-line medicine 0.03 0.02 Beta
Medicine free after surgery to first-line medicine 0.15 0.03 Beta
Time to surgery (3-month rates)
Laser-1st –1.86 0.62 LogNormal
Constant –10.88 1.61 LogNormal
Gamma 2.85 0.57 LogNormal
Resource cost (per year)
Laser-1st OHT £1087 824 Gamma
Laser-1st mild £798 217 Gamma
Laser-1st moderate £1162 598 Gamma
Laser-1st severe £1109 637 Gamma
Medicine-1st OHT £772 283 Gamma
Medicine-1st mild £874 197 Gamma
Medicine-1st moderate £1072 422 Gamma
Medicine-1st severe £1500 744 Gamma
Cost of medicine first line £152 50 Gamma
Cost of medicine second line £159 70 Gamma
Cost of medicine third line £179 74 Gamma
Cost of medicine fourth line £180 74 Gamma
Surgery £1454 299 Gamma NHS Reference Costs 2016–1790
Utility of Markov states per cycle
Laser-1st OHT 0.9034 0.02 Beta
Laser-1st mild 0.905 0.013 Beta
Laser-1st moderate 0.8622 0.021 Beta
Laser-1st severe 0.88 0.023 Beta
Medicine-1st OHT 0.8934 0.022 Beta
Medicine-1st mild 0.9085 0.011 Beta
Medicine-1st moderate 0.8762 0.02497 Beta
Medicine-1st severe 0.8455 0.0206 Beta
Reproduced from Gazzard et al.58 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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Literature search
A total of 1506 papers were identified as part of the literature search. Thirty-four papers45,46,48,50,52–54,73,95–120 were
identified as being relevant to the model, and included information on transition probabilities, utilities and
costs. Overall, data from the trial fit better with the model than data that could be extracted from the 34
papers identified to be relevant. The best utility scores were those from the trial because we were able to
derive trial-arm specific utilities and from the GUI. The values were similar to values published elsewhere in
the literature; for example, Hernández et al.103 reported utilities of 0.8015, 0.8015, 0.7471 and 0.7133 for
OHT and mild, moderate and severe glaucoma, respectively. Stein et al.95 reported values of 0.92, 0.89 and
0.86 for mild, moderate and severe glaucoma, respectively. The values reported in Hernández et al.103 were
used in a sensitivity analysis for the model.
Cost-effectiveness analysis
The average lifetime cost for Laser-1st based on 1000 runs of the PSA was £17,541 per patient, with an
average cost per patient of £20,435 for the Medicine-1st arm and a difference of –£2894. Laser-1st
resulted in an average QALY of 12.5 over the lifetime time horizon, compared with 12.3 for Medicine-1st
(difference of 0.2 QALYs). Laser-1st dominated Medicine-1st in that it was cost saving and resulted in
additional QALYs.
There was a 90% probability that Laser-1st is cost-effective compared with medication at a willingness to
pay £20,000 for a QALY (Figure 10).
Sensitivity analysis
If the utility health state values were substituted for those from Hernández et al.,103 there was no
difference in QALYs between the two groups (an average of 10.6 QALYs per patient over the lifetime time
horizon).
Conclusion
When costs, outcomes and surgery rates were projected to a lifetime time horizon, there was a 90%
probability that Laser-1st is cost-effective. This is similar to the findings of trial-based analysis, strengthening
the finding that Laser-1st is cost saving compared with Medicine-1st.
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FIGURE 10 Cost-effectiveness acceptability curve: probability that Laser-1st is cost-effective for a range of values of
willingness to pay for a QALY.
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Chapter 5 Discussion and conclusions
Summary of findings
This multicentre randomised controlled trial compared initial treatment of OAG or OHT using SLT followed
by medication, if required, with the use of IOP-lowering medication alone. Patient HRQoL, clinical efficacy
and cost-effectiveness were investigated in six NHS settings in the UK. The study demonstrates that initial
SLT is cost-effective, with better clinical outcomes and a trend towards better HRQoL compared with the
prescription of IOP-lowering eyedrops from the outset.
Quality of life
The Laser-1st and Medicine-1st treatment arms showed comparable EQ-5D-5L scores at the trial’s end
point, at 36 months. The trial’s protocol, whereby each eye was treated to an eye-specific IOP target,
led to minimal disease-related differences, such as visual function outcomes. Indeed, VA, VF MD and VF
pattern SD were comparable between the two treatment arms at 36 months (see Table 9), and this was
reflected in similar EQ-5D-5L scores between the two pathways (see Table 8). The above average baseline
HRQoL,82,121–123 weak sensitivity of the EQ-5D-5L to detect glaucoma-specific effects on HRQoL82,123,124 and
relatively short duration of this trial, compared with the time for disease progression, may have contributed
to the lack of superiority of the EQ-5D-5L in the Laser-1st approach. Recent data on patient self-reported
outcome measures (including EQ-5D-5L) now confirm that these may not be sensitive enough to function
as primary end points in clinical trials.125
Glaucoma-specific instruments (e.g. GUI and GQL-15) are better at capturing differences in glaucoma severity
than the effect of treatment side effects on patients’ HRQoL. Indeed, the QoL of patients with glaucoma
has been related to the extent of VF loss when using the GQL-15.8,121,126,127 The GUI attributes less weight
to local side effects and provides generic health outcome measures and measures of glaucoma severity.61
The lack of a significant difference in the GUI and GQL-15 in this study was, therefore, somewhat expected;
each eye was treated to target and stringent controls over disease progression minimised any substantial
differences in disease severity.
The GSS evaluates a visual and an ocular comfort-related domain. The six non-visual ophthalmic symptoms
are formed around an ocular comfort domain (burning/smarting/stinging, tearing, dryness, itching,
soreness/tiredness and a feeling of something in the eye), and are related to treatment side effects and their
measures. The patients were asked to rate their difficulties around blurry/dim vision, hard to see in daylight,
hard to see in dark places and haloes around lights, in relation to the four visual ophthalmic symptoms.
The GSS has been shown to correlate well with traditional measures of visual function (such as VA and VF),62
which in this study’s end point were comparable between the two treatment arms. Repeated-measures
analysis showed worse GSS scores for the Medicine-1st arm at five out of six time points over the course
of the 36 months of the trial. Better GSS scores for the Laser-1st arm may represent differences that arise
from eyedrop use (64.6% of the patients in the Medication-1st arm were using only one drop per day)
(see Table 11), but potentially reflect differences in baseline scores between the two treatment arms
(83.3 for the Medicine-1st arm and 81.4 for the Laser 1st arm) (see Table 7).
Clinical efficacy
The treatments were equally effective in lowering IOP and reaching the target IOP for the first time, with
89.6% of the Medicine-1st eyes reaching target at the first planned follow-up visit, compared with 91.0%
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of the Laser-1st eyes (see Table 10). By 3 years, however, 95% of the Laser-1st eyes were at target IOP,
compared with 93.1% of the eyes treated with Medicine-1st. Although Medicine-1st provided more eyes
at target IOP at 12 months (96.2% for Medicine-1st compared with 94.7% for Laser-1st) (see Table 10),
Laser-1st achieved more eyes at target IOP over the second and the third years of treatment. Interestingly,
the percentage of eyes with severe OAG that were at target IOP after the second and third years of
treatment was higher in the Medicine-1st arm than in the Laser-1st arm (89.5% compared with 87.5%,
respectively, at 24 months and 85.7% compared with 84.6%, respectively at 36 months); the proportions
of severe OAG eyes achieving IOP target at 12 months were comparable (91.3% and 91.5%, respectively).
A possible explanation may be the limit to which SLT may reduce IOP; severe OAG is likely to have low
IOP targets, which may be easier to achieve with more than one medication. A number of studies have
reported that SLT reduces IOP by 15–32%,128–134 and another study found a reduction of up to 29.4%
at 6 months, up to 30% at 12 months, up to 27.8% at 2 years and up to 25.1% at 3 years.135
Overall, IOP was at target for 93% of the Laser-1st visits, compared with 91% of the Medicine-1st visits,
over the 36-month duration of the trial. IOP control with topical medication (eyedrops) may rely on patient
concordance with treatment; indeed, one report94 found that IOP-lowering eyedrops were available to
patients for only 69% of the time, whereas concordance has been reported to range between 76% and
86%. More discouraging figures have been reported for patients on multiple eyedrops.136,137 In this trial,
however, self-reported concordance was very high, with patients’ concordance reportedly improving
during the 36 months of treatment (see Tables 16 and 17). SLT has also been proposed to provide better
diurnal IOP stability, because of its continuous effect on the trabecular meshwork, in contrast to the
episodic administration of medication.138–141 This trial showed a comparable IOP fluctuation between
Medicine-1st and Laser-1st (2.5 mmHg and 2.3 mmHg, respectively).
By 36 months, 78.2% (95% CI 74.7% to 81.4%) of the eyes treated with Laser-1st were at target without
the need for any topical IOP-lowering medication (eyedrops). In comparison, in 64.6% of eyes treated with
Medicine-1st only a single eyedrop was necessary to control IOP. Primary SLT gave eyedrop-free IOP control
for at least 36 months to 74.2% of patients (95% CI 69.3% to 78.6%), substantially higher than reported
in previous studies that used less stringent success criteria and which used SLT exclusively as the primary
treatment.37,142–144 Prior treatment and more severe disease have been suggested to reduce the magnitude
of IOP lowering with SLT,37,38,142–144 possibly explaining the results of this trial in treatment-naive patients. Pre-
trial activities with glaucoma patients (LAG) identified eyedrop-free disease control as the most desired
outcome, with 90% of a patient focus group feeling that even unilateral eyedrop freedom is beneficial.
Concerns about eyedrop use, particularly associated with challenges from cognitive and physical impairment,
were rated as a priority by patients in the James Lind Alliance survey of sight loss research questions.145
By 36 months, rates of disease deterioration were higher in the Medicine-1st arm than in the Laser-1st arm
[5.8% (36 eyes) vs. 3.8% (23 eyes), respectively], despite the treat-to-target design, tailoring treatment
intensity to disease severity and treatment response. The vast majority of disease progression happened in
eyes with OAG (33 out of 36 eyes in the Medicine-1st arm and 21 out of 23 eyes in the Laser-1st arm)
(see Table 12). Additionally, there were more treatment escalations over 36 months in the Medicine-1st
arm (348, compared with 299 in the Laser-1st arm).
Upwards (22 in the Medicine-1st arm and 26 in the Laser-1st arm) and downwards (16 in the Medicine-1st
arm and 15 in the Laser-1st arm) target IOP revisions were overall balanced between the two treatment
arms. By 36 months, 11 eyes in the Medicine-1st arm, but none in the Laser-1st arm, had required
IOP-lowering surgery.
Safety
This trial demonstrates a greater safety of SLT than previously reported, with low rates of SLT-related
AEs.143 Rates of systemic AEs were balanced between the two treatment arms, indicating a safe treatment
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pathway for both Medicine-1st and Laser-1st (i.e. no excess cardiac or pulmonary events in the Medicine-1st
arm and no systemic AEs as a result of SLT) (see Tables 13 and 14). Differences in the rates of cancer
diagnoses and deaths between the two treatment arms (see Table 14) are attributable to chance, with no
medical link between the treatments that were administered and the events that took place.
Eyedrop-related systemic and ophthalmic AEs were reported by more patients and more often in the
Medicine-1st arm (see Table 13). Ophthalmic AEs led to a change in treatment for 11.3% of the patients
treated with Medicine-1st, when IOP was otherwise well controlled.
Selective laser trabeculoplasty resulted in at least one transient AE in 34.4% of the patients treated with
Laser-1st. Out of 776 SLT procedures, one patient developed an IOP spike requiring treatment, compared
with reported rates of up to 28.8%, possibly because treatment was administered at an earlier stage of
disease in this trial.143 The IOP check conventionally done 2 weeks after SLT did not change management
for any of the patients and consequently appears unnecessary.
The ocular comorbidities developed during the trial spanned a range of conditions commonly seen in
patients of the age group of this cohort (retinal vascular occlusions, diabetic retinopathy, retinal tears and
detachments, macular degeneration, etc.) (see Table 15). The rate of cataract surgery was lower in the
Laser-1st arm (13 eyes in the Laser-1st arm, compared with 25 eyes in the Medicine-1st arm) (see Table 15),
supporting existing evidence that IOP-lowering eyedrops are associated with a greater incidence of nuclear
cataract and earlier need for surgical removal.12,59,146–148
Economic evaluation
The Laser-1st approach resulted in a significant reduction in the cost of surgery and IOP-lowering
medication, with an overall cost saving to the NHS of £451 per patient in specialist ophthalmology costs.
The trial-based economic evaluation found that there is a 97% probability that SLT is a cost-effective
treatment for OAG and OHT at a £20,000 willingness to pay for a QALY, from an ophthalmology cost
perspective. Resource use information was collected from patient files and trial monitoring data and hence
is likely to be complete, with limited bias as a result of loss to follow-up or missing data. Including non-
eye-related health-care costs alongside ophthalmology costs, the average cost per patient for Laser-1st
remained less than that for Medicine-1st, but the differences between the two groups were not significant,
with the wide CIs resulting in a 68% probability that Laser-1st is cost-effective compared with Medicine-1st.
Non-ocular health-care cost data were, however, based on self-reported health-care resource use and
may be unreliable or incomplete. Expensive systemic AEs unrelated to OHT or OAG, such as cancer, may
have also skewed the cost results. In the health economic decision model, in which costs and utilities are
projected for the lifetime of patients, there is a 90% probability that Laser-1st is cost-effective compared
with Medicine-1st at a willingness to pay £20,000 for a QALY health-care cost perspective, with an
average cost saving per patient to the NHS of £2894.
Previous economic assessments have attempted to estimate the relative costs of SLT using only economic
modelling or estimates of the treatment costs, instead of a direct cost assessment plus modelling.50,51,53
Compared with mono or multiple drug therapy, and allowing for repetition of SLT within 2–3 years, cost
savings have been predicted at 6 years for a Canadian health-care system.46 The present study, conducted
in a NHS setting following pragmatic clinical approaches for the treatment of OAG/OHT, indicates that SLT
is cost-effective over a 3-year period and is likely to remain cost-effective over the lifetime of the patients.
These findings have important implications for patients and health-care systems. Patients are concerned
about the use of IOP-lowering eyedrops,145 and widespread uptake of the Laser-1st strategy would lead to
an eyedrop-free interval of at least 36 months for three-quarters of patients, while also providing savings
for the NHS. If necessary, additional SLT may further increase the duration of this eyedrop-free window.
Patients with OAG have an average life expectancy from diagnosis of 9–13 years,149–151 and so an eyedrop-
free period of ≥ 3 years may significant increase the quality of their remaining life. The requirement for
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intense medical or surgical regimes may be deferred or completely averted by SLT and potentially with
improved surgical success rates and still lower cost.31,33,34
The health economic decision model has some limitations. First, the mortality rate used is not glaucoma
specific. Rather, the same all-cause mortality rate was applied across all health states. This is a reasonable
assumption given that studies have not found a difference in all-cause mortality rates between patients
with and without glaucoma.149 There is, however, an increased risk of cardiovascular disease in older
patients (aged > 75 years), which was not incorporated into the model. This is unlikely to have made a
significant impact on the results of the model, given the small difference in OAG progression between the
two arms.
The lifetime economic model originally set out to include variables from other studies in the literature,
including costs, utilities and disease progression. As noted in other studies that have modelled the
progression of OAG, there is heterogeneity in how OHT and OAG are defined, making it difficult to
incorporate such values into glaucoma models.73 Burr et al.73 conducted a systematic review of studies for
glaucoma progression and identified 1-year progression probabilities for mild to moderate glaucoma,
moderate to severe glaucoma and severe glaucoma to visually impaired. The progression values for the
two health states that overlap with our model for Medicine-1st patients are different from those observed
in the LiGHT trial; higher for mild to moderate progression (0.2 in Burr et al.73 vs. 0.07 in the LiGHT trial)
and lower for moderate to severe progression (0.07 in Burr et al.73 vs. 0.17 in the LiGHT trial). This
difference is likely to be a result of differences in the populations used to determine transitions
probabilities, as the values for Burr et al.73 are from observational studies of people at different stages of
OAG, whereas the LiGHT trial recruited patients newly diagnosed with OHT or OAG. It may also be as a
result of differences in how the various stages are defined, with Burr et al.73 restricting the definition to
mean definition score only, omitting an OHT health state and including an additional visual impairment
state. Costs were also more suitably obtained from the trial or NHS reference costs90 given that most
studies report costs for medication for OHT and OAG health states, or the costs for eyedrops progression,
ophthalmology appointments and trabeculectomy (glaucoma surgery) only.77 Our model is novel, in that
we were able to project medication and trabeculectomy costs over the lifetime of patients while modelling
the health-care costs associated with OHT and OAG health states separately, using LiGHT trial data. As
discussed, our utility values for health states are similar to those quoted in other studies;73,95,103 modifying
these has limited impact on the results, particularly as using published data means that we are unable to
use utilities specific to trial arms.
Strengths and limitations
This study mirrored pragmatic clinical practice by tailoring treatment to the patient. Individual IOP targets
were based on pre-treatment IOP and disease severity, and adapted both to treatment response and to
progression of the disease. Consequently, the concluding findings on disease progression, achievement
of target IOP and cost are highly relevant to normal clinical practice. The ‘treat-to-target’ design with
computerised decision-supported treatment interventions and follow-up intervals captured the complexity
of real-life clinical decision-making, but also allowed objective and unbiased decisions based on clinical
observations.
This trial was unmasked. An unmasked design was essential to capture any treatment effects on patients’
perception, which is clinical reality. As an important benefit of SLT is an eyedrop-free treatment window;
a study design requiring a treatment arm with placebo eyedrops would have prevented assessment of
benefits attributable to IOP control without the use of medication. The impact of treatment on subsequent
medication-taking behaviours and concordance was also of interest and will be fully revealed in the
extension of this trial. Similarly, treating clinicians had to be unmasked to be able to choose appropriate
treatment escalations.
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The EQ-5D-5L questionnaire, a generic tool eliciting utility values in multiple settings, may not have been
the most sensitive tool to investigate HRQoL in the two treatment arms for a 3-year trial, but is a
requirement for a NICE cost–utility analysis. OAG can be asymptomatic, even at levels sufficient to make
driving unsafe.152 Although potentially associated with significant visual impairment over longer periods,
only small changes in vision occurred over the 36 months duration of the trial, and this finding may be
related to the lack of a difference in the primary outcome at 36 months.
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Chapter 6 Conclusions
In summary, this trial shows that treating newly diagnosed OAG and OHT patients with SLT can safelyprovide predominantly eyedrop-free IOP control over a minimum of 3 years, with less intense treatment,
fewer AEs and a reduced need for ocular surgery at a lower cost per QALY than standard medical therapy
alone, with a similar effect on patients’ generic HRQoL.
Implications for health care
The results of this randomised controlled trial are widely generalisable, as patients with OHT and both
low- and high-pressure OAG were included, from a range of backgrounds and ethnic origins. This trial focused
on newly diagnosed, treatment-naive patients with OHT and/or mild or moderate OAG; the results should,
therefore, be interpreted with caution in relation to the efficacy of SLT in advanced OAG stages, or in eyes
previously treated for high IOP. There are important implications for resource-poor health-care settings,
where access to medication is a major barrier to glaucoma treatment. Adequate eyedrop-free IOP control
for years after is a promising treatment paradigm for regions of Africa where glaucoma prevalence is high.
Longer follow-up, already under way, will permit us to answer further questions regarding the effect of
prior SLT on later medication-taking behaviour, treatment intensity and longitudinal HRQoL.
The data support a change in practice; however, clinicians need to consider the perceived necessity of
monitoring visits by the patient, in the absence of daily medication, as has been suggested by in the past for
other chronic illnesses.153 Primary SLT is a safe, clinically efficient and cost-effective alternative to eyedrops
that can be offered as a first-line treatment to patients with OAG or OHT, in need of IOP reduction.
Recommendations for research
This study addresses the initial 36-month period after initiation of treatment for OAG and/or OHT. OAG
and OHT are chronic conditions and treatment is almost always lifelong. Longitudinal research into the
clinical efficacy of SLT as a first-line treatment could specify the long-term differences (if any) of disease
progression, treatment intensity and ocular surgery rates between a Laser-1st and a Medicine-1st pathway,
as well as any effect on subsequent medication-taking behaviours. Longitudinal HRQoL in OAG and OHT
will also help clinicians understand the impact medical treatment has on patients over a longer period of
time, where more intense medical treatment might become necessary.
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Appendix 1 Recruiting sites
TABLE 22 Recruiting sites, local PIs and screening start and end dates
Participating centre Local PI Screening start date Screening end date
MEH, City Road Campus Mr Gus Gazzard October 2012 October 2014
MEH at St George’s Hospital Mr Gus Gazzard October 2012 October 2014
MEH at Northwick Park Hospital Mr Nicholas Strouthidis
Mr Hari Jayaram
October 2012 October 2014
Royal Victoria Hospital, Belfast Ms Sarah Wilson November 2013 October 2014
Guy’s and St Thomas’ Hospital Mr Sheng Lim July 2013 October 2014
Hinchingbrooke Hospital Professor Rupert Bourne July 2013 October 2014
Norfolk and Norwich University Hospitals
NHS Foundation Trust
Mr David Broadway July 2013 October 2014
York Hospital Mr Timothy Manners
Ms Joanna Liput
November 2013 October 2014
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Appendix 2 Definitions of open-angle glaucoma,
ocular hypertension and treatment requirements
We have used the NICE recommended thresholds for initiating treatment,1 with stringent diagnosticdefinitions of disease (OAG or OHT) for entry into the study.
Diagnosis of open-angle glaucoma and treatment requirements
Primary OAG is defined as an open drainage angle (no iridotrabecular contact on non-indentation
gonioscopy in primary position, trabecular meshwork visible over 360°), with no secondary causes (such as
trauma):
l and reproducible glaucomatous VF defects as tested by the Swedish Interactive Threshold Algorithm on
the Humphrey Visual Field Analyser (i.e. reproducible defect, in at least, of two or more contiguous
points with a p-value < 0.01 loss or greater, or three or more contiguous points with a p-value < 0.05
loss or greater, or abnormal Glaucoma Hemifield Test)
l or GON with localised absence of the neuroretinal rim, or cup disc ratio of ≥ 0.7, or asymmetry of cup
disc ratio of ≥ 0.2 in similar-sized eyes/optic discs
l and deemed to require treatment in the opinion of the treating (fellowship-trained) glaucoma specialist.
Subjects with pseudo-exfoliation are eligible (as for EMGT I82).
Subjects with GON and IOP in the normal range are therefore eligible. ‘Phasing’ (diurnal IOP pressure
measurements) will be performed at the discretion of the treating clinician, and, if performed, the
maximum IOP recorded will be used as that day’s measurement.
Diagnosis of ocular hypertension and treatment requirements
Ocular hypertension with IOP > 21 mmHg and requiring treatment as per NICE guidelines.1 NICE OHT
guidelines treat four categories of OHT on the basis of CCT and age (the rest are monitored for 3–5 years).
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Appendix 3 Video script
This video has been designed to inform you about a research study that is ongoing at Moorfields EyeHospital. The video will introduce you to glaucoma and ocular hypertension, the various treatment
options that are available and will eventually invite you to take part in a research study investigating the
quality of your life after treatment. We would be grateful if you could spend 5–10 minutes watching
this video.
Glaucoma is a disease of the optic nerve, which connects the eye to the brain. Glaucoma slowly progresses
over a period of years; at the early stages people may not notice anything abnormal, but in advanced
disease people may notice loss of vision. At the early stages, glaucoma can be treated with eyedrops or
a laser treatment, which aim to control the condition and minimise future damage. Early diagnosis is
important because any damage cannot be reversed. If glaucoma is left untreated, it can cause visual
impairment. Glaucoma may be caused by raised eye pressure, but sometimes glaucoma develops despite
a normal pressure inside the eyes, owing to a poorer blood supply or a weaker optic nerve.
Ocular hypertension is a condition where the pressure of the eyes is above normal limits, without,
however, this causing any damage to the optic nerve. Some people have higher pressures than others.
It has been shown that ocular hypertension puts people at a higher risk for developing glaucoma. Some
people with ocular hypertension may, however, never develop glaucoma.
The pressure of your eyes is important, as your eyes function properly under a certain amount of pressure.
If this pressure increases the optic nerve can be damaged. The amount of damage may depend on how
high the pressure is, how long it lasts, and whether there is a poor blood supply or other weaknesses of
the optic nerve. By lowering the pressure damage is slowed down.
At the moment, in the NHS, nearly all patients who have glaucoma or ocular hypertension are treated by
eyedrops. Once started, eyedrops usually have to be continued for life. Not all patients like using eyedrops
daily, however, and these patients might be suitable to a gentle laser therapy called selective laser
trabeculoplasty. This laser treatment is not experimental; it is used commonly in the UK and for a number
of years in the United States and its efficacy has been proven. At the moment the laser treatment is not
offered as a first-line treatment in the NHS.
This study is designed to investigate the quality of life in patients treated first time either with eyedrops
or with laser and is being funded by the National Institute for Health Research. The study will use
questionnaires that the patients will have to fill in every 6 months. A secondary aim is to assess the cost
of these treatments to the NHS.
Because we don’t know which treatment will prove preferable for the patients’ quality of life or which
treatment is more cost-effective for the NHS, patients in this study will be assigned randomly to one of
the two treatments and the two groups will then be compared. This type of study is called a randomised
controlled trial, where half the patients will be randomly assigned by a computer to eyedrops and half will
be assigned to laser treatment. If we assigned you to a group we might show preference to a specific
treatment and if you were to choose, you might be biased towards one treatment.
Participation in this study is entirely voluntary. If you decide not to take part this will have no effect on the
quality of care you receive at Moorfields Eye Hospital. If you decide to take part you will only be asked to
attend the clinic one extra time compared with the usual clinic, but we can reimburse your travel expenses.
The reason we will ask you to come one extra time is to give you time to think about the study and allow
you to ask us any questions you might have.
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If you decide to take part in this study you will be monitored by our specially trained optometrist and you
will do the exact same tests you would do in a normal clinic. This is because the study is a real-life study,
investigating your quality of life. This study will last in total 5 years, but each patient will be monitored for
6 years after the treatment is started. For this period of time you will be asked to attend the clinic between
five and seven times. If you do not take part in the study you will be asked to attend the clinic six to seven
times. After the end of the study you will continued to be monitored by the glaucoma clinics at Moorfields
Eye Hospital as usual.
If you decide to take part you will be asked to fill in a questionnaire about your health and about your
eyes. You will then be assigned to having drops or laser and you will be seen a few weeks later to assess
if the treatment is working, just as we would if you were not in the study. Twice a year we will send you
a questionnaire by post, which after filling in you can return to us in a pre-paid envelope that we will
also send.
As every treatment, the treatments in this study might have some side effects. Eyedrops are used for
approximately 30 years and can have mild or more severe side effects. Drops can cause mild discomfort
or redness of the eyes, which usually settle soon, but in some cases they might make asthma worse.
We will make sure we ask you all the necessary questions about your health before prescribing any drops.
Some types of eyedrops should not be given to pregnant women. Any woman who is pregnant or who is
planning to become pregnant should therefore not take part in this study. If a woman taking part in the
study becomes pregnant she should let the research team know immediately. If the drops are not lowering
your eye pressure enough you will be offered different or additional eyedrops.
The laser has been used successfully for 10–20 years. It is not a surgery and it is safe, easy and painless
to deliver. In some people it might cause a small discomfort for a few days, which can be treated with
anti-inflammatory eyedrops. Very rarely the laser might cause the eyes to be blurry for a few weeks or it
may cause the pressure of the eyes to increase. If this happens we will give you drops to use for a few
days. Laser treatment is effective in 80–90% of patients and its effect might wear off after a few years.
If this happens the laser can be repeated once more. If for some reason we still need to reduce your eye
pressure we will give you drops.
This study has no direct risks or benefits to you, as it is designed to mimic normal clinical practise. This
means that you will be doing exactly what you would be doing in a normal glaucoma clinic and nothing
additional to that. If during the study you decide you don’t want to take part any more you can withdraw
without providing a reason and without this affecting your care at Moorfields Eye Hospital. If you choose
to withdraw you will then be monitored by a normal clinic. If you decide to take part you will be assigned
an ID and all the information will be kept strictly confidential.
Two of the patients who have already taken part in our study have kindly agreed to explain the reasons
they decided to participate and their experience so far.
Having explained why Moorfields Eye Hospital is conducting this study I hope you will be willing to
consider taking part. My colleagues will now give you an information sheet about this study and will be
able to answer any further questions you might have in relation to the study.
Thank you very much for your time.
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Appendix 4 Selective laser trabeculoplasty
delivery protocol
T raining was given to all treating surgeons before recruitment and at least one laser treatment wasobserved by the chief investigator. The treating surgeon was the local PI or a fellowship-trained
glaucoma specialist who was eligible to apply for a UK consultant surgeon post or for inclusion on the UK
General Medical Council specialist register and who had performed at least 25 previous SLT treatments.
Selective laser trabeculoplasty was delivered to 360° of the trabecular meshwork, with one 360° retreatment
as the first escalation of treatment if required. The model of SLT laser used was not restricted, and the
wavelength and spot size were the same. To minimise variation between surgeons, standardisation was
achieved by a stringent protocol defining laser settings and technique.
Pretreatment with iopidine (0.5% or 1%) at least 15 minutes before treatments was mandatory, unless
contraindicated for medical reasons, in which case alternative medications such as oral acetazolamide
[Apraclonidine (Novartis Pharmaceuticals UK Ltd)] could be used. If no prophylaxis against IOP spikes was
used, close post-treatment monitoring of IOP for 2 hours was necessary.
One hundred non-overlapping shots (25 per quadrant) of a preset 3 nanoseconds duration and a preset
400 μm spot size were used, with the laser energy varied from 0.3 mJ to 1.4 mJ by the clinician using any
laser gonioscopy lens (as long as the appropriate magnification was observed, e.g. ‘Latina’ was acceptable
but ‘Magnaview’ was not). The desired end point was the production of a few fine ‘champagne bubbles’;
larger gas bubbles and trabecular meshwork blanching were not acceptable, and if seen the operator
should have titrated the power downwards in 0.1-mJ increments. Pigmented trabecular meshwork will
have required lower energy (from 0.3 mJ to 1.2 mJ) than non-pigmented and it was advisable to start
treatments at 0.4 mJ. The Goldmann applanation tonometry IOP was measured 1 hour after treatment.
After treatment with SLT, patients were not asked to use anti-inflammatory eyedrops routinely; however,
they were provided with a bottle of topical non-steroidal anti-inflammatory eyedrops for use only if they
were in significant discomfort, despite simple oral analgesia such as paracetamol. [This is now standard
practice in most units worldwide (Mark Latina, Tufts University School of Medicine, MA, USA, personal
communication).] Topical steroids were not to be permitted post laser. Demonstrations of correct eyedrop
technique were given at baseline and whenever needed thereafter.
Any rise in IOP of > 10 mmHg or that puts the patient at risk of visual loss was treated at the discretion
of the treating ophthalmologist with an earlier recheck of IOP (e.g. at 2 hours, 1 day or 1 week) and/or
a short-term course of topical or systemic aqueous suppressants as necessary. An IOP rise necessitating
medical treatment or an extra visit alone would constitute an AE and be independently logged as such.
The first post-SLT follow-up was at 2 weeks for an IOP check and assessment of potential side effects. No
reintervention/treatment escalation decisions for non-response were made at this point; a further follow-up
6 weeks later was scheduled to allow time for the full effects of laser to occur. Patients at target 8 weeks
after SLT were subsequently reviewed as per the interval determined by the severity category. Patients not
at target after a single SLT received another treatment of 360° (100 spots) at the same energy settings,
with re-evaluation after 2 weeks. After retreatment, a 6-week follow-up was given whether at target or
not, unless, in the opinion of the treating clinician, a dangerously high IOP posed a significant risk to
vision, in which case earlier follow-up was allowed to avoid an unsafe delay in medical therapy.
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It is possible that an IOP rise following SLT could be severe enough to prevent a safe repeat of SLT should
the target not have been met in future, particularly with more severe glaucoma. In this case, treatment
escalation with eyedrops rather than repeating the SLT was permitted. This required an algorithm over-ride
and thus was automatically logged and monitored. This may have occurred as an immediate (but transient)
or persistent post-SLT pressure rise. Any immediate IOP rise > 40 mmHg despite pre-treatment iopidine or
any rise of > 5 mmHg that persisted 8 weeks after laser would usually prevent further SLT treatment. After
two SLT treatments, participants in the Laser-1st pathway embarked on medical treatment and followed
the Medicine-1st algorithms. If the participant subsequently underwent drainage surgery which failed in
the course of the trial, the step-wise medical intervention algorithm was initiated again and further SLT
was not permitted.
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Appendix 5 Questionnaire: sample patient
response
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Appendix 6 Patient and public involvement
survey sent to patients
XXXX
XXXX
XXXX.
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Appendix 7 Frequency of data monitoring across
sites
TABLE 23 Frequency of data monitoring across sites
Site Patients (n) Monitored (n) Monitored (%) Notes
Guy’s and St Thomas’ Hospital 106 106 100.0 January 2015–February 2016
Guy’s and St Thomas’ Hospital
(repeat)
106 30 28.3 April 2016–October 2017
Hinchingbrooke Hospital 82 38 46.3
York Hospital 37 19 51.4
Royal Victoria Hospital, Belfast 30 11 36.7
Norfolk and Norwich University
Hospitals NHS Foundation Trust
89 40 44.9
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Appendix 8 Recruitment
TABLE 24 Recruited patients by month and by site
Date Monthly target Cumulative overall target Actual recruitment
Cumulative actual
recruitment
October 2012 10 10 7 7
November 2012 17 27 24 31
December 2012 17 44 10 41
January 2013 17 61 19 60
February 2013 17 78 13 73
March 2013 17 95 11 84
April 2013 17 112 12 96
May 2013 17 129 16 112
June 2013 17 146 7 119
July 2013 26 172 33 151
August 2013 39 211 22 173
September 2013 39 250 27 200
October 2013 39 289 39 239
November 2013 39 328 39 278
December 2013 39 367 40 318
January 2014 39 406 47 365
February 2014 39 445 36 401
March 2014 39 484 45 446
April 2014 39 523 47 493
May 2014 39 562 23 516
June 2014 39 601 37 553
July 2014 39 640 53 606
August 2014 39 679 26 632
September 2014 39 718 38 670
October 2014 39 718 49 719
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Appendix 9 Protocol deviations and violations
TABLE 25 Protocol deviations and violations over the 36 months of the trial
Patient ID Site Date of event Violation/deviation Preventative action
MEH-070 MEH 27 February 2013 Violation: ineligible patient
randomised
Any patient who is judged to
have angles < 10°, or where
there is a conflict of diagnosis,
should be checked by the chief
investigator/PI prior to
randomisation
YOR-246
YOR-265
YOR-286
YOR-287
YOR-319
York 8 January 2014 Deviation: health-care assistants
have been performing SITA fast
visual fields instead of SITA
standard
Research manager has sent an
e-mail to all centres (PIs and
co-ordinators) to ensure that
patients are tested using SITA
standard and not SITA fast.
VF are now being done by the
research team in York rather
than health-care assistants
HIN-340 Hinchingbrooke 15 January 2014 Deviation: after the patient was
randomised they decided to
withdraw as they wanted to
have only one of the two
treatments
E-mailed the site explaining
that patients who are adamant
about receiving a particular
treatment should not be
consented to participate as this
is a randomised trial. Site is
happy to continue with this
guidance. Mr Bourne confirmed
that the patient did not express
a preference to a treatment prior
to randomisation, but once
randomised they had made a
preference. Patient has been
withdrawn and will have their
preferred treatment on the NHS
GST-472 Guy’s and
St’ Thomas’
14 April 2014 Violation: ineligible patient
randomised
VF MD more than the eligibility
criteria
YOR-265 York 17 December 2013;
14 January 2014
Deviation: patient previously
randomised to SLT. Patient did
not attend 2-week IOP check
and York hospital rescheduled
the appointment. At this
appointment, the algorithm
was updated which should not
have been
Violation: HRT test was not
done and data not entered on
to the algorithm on the day of
the appointment. Data were
also entered for the wrong
follow-up visit as a result of
data being entered at the IOP
check visit when this should
not have been entered. The
patient was then prescribed
eyedrops as an increase in
treatment as a clinical decision
over-riding the algorithm
Provided intense training for all
team members on 28 January
2014
continued
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TABLE 25 Protocol deviations and violations over the 36 months of the trial (continued )
Patient ID Site Date of event Violation/deviation Preventative action
BEL-613 Belfast 8 August 2104 Deviation: patient was recruited
and randomised to laser. As
the patient’s IOP increased,
Ms Wilson decided to start
eyedrops and not go ahead
with the laser
GST-486 Guy’s and
St’ Thomas’
28 April 2014 Violations: ineligible patient
randomised owing to VF MD
criteria
GST-512
GST-156
GST-261
GST-541
GST-531
GST-552
GST-585
GST-598
GST-596
GST-430
GST-570
GST-544
GST-561
GST-571
GST-530
GST-358
GST-239
Guy’s and
St’ Thomas’
20 November 14 Violations: appointment
schedule had not been
followed
Has been noted and corrected.
Centre retrained on protocol
NOR-349 Norfolk and
Norwich
20 January 2014 Violation: patient not eligible
owing to PDS
GST-178 Guy’s and
St’ Thomas’
11 January 2016 Deviation: third SLT done in the
left eye
GST Guy’s and
St’ Thomas’
Violation: Mr Lim had advised
all patients to take Acular
(ketorolac) for 3/7 t.i.d.
following SLT. However, the
protocol and SOP for SLT states
‘Acular as required only’ for
everyone is indeed at variance
with the agreed protocol
Acular for everyone is indeed
at variance with the agreed
protocol, but consistency with
what has already been done
within a unit is important. It
was proposed that repeat lasers
get the same as what Mr Lim
has already done
ID, identification; PDS, pigment dispersion syndrome; SITA, Swedish Interactive Threshold Algorithm; t.i.d., ter in die
(three times a day).
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
Appendix 10 Results of sensitivity analyses
TABLE 26 Results of sensitivity analyses
Approach
Adjusted mean differencea
(Laser-1st –Medicine-1st) 95% CI
1. Using exact dates 0.007 –0.009 to 0.022
2. Adjusted for variables associated with missingness 0.011 –0.008 to 0.030
3. Multiple imputation 0.016 –0.004 to 0.035
4. Mapping algorithm 0.019 –0.005 to 0.042
5. Data recorded within 3 months of 36 months 0.012 –0.007 to 0.031
6. Robust SEs 0.012 –0.007 to 0.031
7. Beta regression 0.002 –0.010 to 0.013
a Mean difference is adjusted for baseline score, severity, centre, baseline IOP and number of eyes affected at baseline.
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Appendix 11 Details of ophthalmic- and
laser-related adverse events
TABLE 27 Details of ophthalmic- and laser-related AEs
Medicine-1st Laser-1st Total
n of
events
n (%) of
patients
n of
events
n (%) of
patients
n of
events
n (%) of
patients
Other ophthalmic-related AEs 744 118 (32.6) 459 117 (33.0) 1041 235 (32.8)
Conjunctival injection 109 61 (16.9) 33 25 (7.0) 142 86 (12.0)
Ocular irritation, discomfort or dry eye 239 125 (34.5) 147 97 (27.3) 386 222 (31.0)
Itching 103 51 (14.1) 73 44 (12.4) 176 95 (13.2)
Stinging on instillation 89 53 (14.6) 18 11 (3.1) 107 64 (8.9)
Optic disc haemorrhage 4 4 (1.1) 8 7 (2.0) 12 11 (1.5)
Macular haemorrhage 0 0 (0) 0 0 (0) 0 0 (0)
Subconjunctival haemorrhage 9 8 (2.2) 2 2 (0.6) 11 10 (1.4)
Cataract 14 13 (3.6) 19 17 (4.8) 33 30 (4.2)
Blurred vision 19 18 (5.0) 12 12 (3.4) 31 30 (4.2)
Change in vision 16 14 (3.9) 9 9 (2.5) 25 23 (3.2)
Floater(s) 5 5 (1.4) 11 8 (2.3) 16 13 (1.8)
Flashes 4 4 (1.1) 8 7 (2.0) 12 11 (1.5)
Conjunctivitis 8 8 (2.2) 6 5 (1.4) 14 13 (1.8)
Watery eye 8 7 (1.9) 13 11 (3.1) 21 18 (2.5)
Glare 4 4 (1.1) 6 5 (1.4) 10 9 (1.3)
Pain/sore eye 10 10 (2.8) 8 8 (2.3) 18 18 (2.5)
Blepharitis 6 6 (1.7) 0 0 (0) 6 6 (0.8)
Swollen eye(s) 3 3 (0.8) 1 1 (0.3) 4 4 (0.6)
Photophobia 4 4 (1.1) 4 3 (0.8) 8 7 (1.0)
CRVO 2 1 (0.3) 0 0 (0) 2 1 (0.1)
BRVO 1 1 (0.3) 2 1 (0.3) 3 2 (0.3)
Diabetic retinopathy 0 0 (0) 1 1 (0.3) 1 1 (0.1)
Diabetic macular oedema 0 0 (0) 3 2 (0.6) 3 2 (0.3)
Other laser-related AEs 1 1 (0.3) 51 47 (13.2) 52 48 (6.7)
Photophobia 0 0 (0) 21 20 (5.6) 21 20 (2.8)
Hyperaemia 0 0 (0) 3 3 (0.8) 3 3 (0.4)
Discomfort 0 6 6
Breaks taken during procedure 0 0 0
Fewer laser shots 0 3 3
Visualisation of angle/other angle issues 0 5 5
BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion.
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Appendix 12 Medical contacts
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TABLE 28 Clinic visits and medical contacts over 36 months (data for the previous 6 months for each follow-up point)
Baseline 6 months 12 months 18 months 24 months 30 months 36 months
Medicine-1st
(n= 362)
Laser-1st
(n= 356)
Medicine-1st
(n= 326)
Laser-1st
(n= 329)
Medicine-1st
(n= 317)
Laser-1st
(n= 317)
Medicine-1st
(n= 302)
Laser-1st
(n= 302) Medicine-1st Laser-1st Medicine-1st Laser-1st Medicine-1st Laser-1st
Eye related, mean (SD)
Optician 0.898 (0.691) 0.874
(0.729)
0.336 (0.600) 0.464
(0.789)
0.364 (0.569) 0.422
(0.660)
0.397 (0.611) 0.412
(0.714)
0.409 (0.546) 0.456
(0.597)
0.394 (0.637) 0.399
(0.631)
0.497 (0.718) 0.492
(0.721)
General practitionera 0.192 (0.477) 0.186
(0.493)
0.095 (0.408) 0.116
(0.630)
0.073 (0.363) 0.050
(0.314)
0.05 (0.273) 0.053
(0.412)
0.112 (0.493) 0.076
(0.387)
0.081 (0.378) 0.1
(0.539)
0.125 (0.729) 0.122
(0.631)
General practitioner
nurse
0.045 (0.363) 0.074
(0.371)
0.074 (0.378) 0.068
(0.317)
0.064 (0.304) 0.065
(0.517)
0.086 (0.384) 0.034
(0.246)
0.090 (0.407) 0.026
(0.229)
0.121 (0.817) 0.053
(0.254)
0.063 (0.319) 0.072
(0.339)
Social worker 0.003 (0.053) 0.003
(0.053)
0.003 (0.055) 0.003
(0.055)
0.003 (0.056) 0 0 0 0.003 (0.058) 0.003
(0.057)
0 0 0 0.003
(0.058)
Home care worker 0.003 (0.053) 0.008
(0.092)
0.006 (0.078) 0 0 0 0.003 (0.058) 0 0 0 0 0 0 0
Other community
services
0 0 0.003 (0.056) 0.003
(0.056)
0 0 0.007 (0.083) 0.010
(0.175)
0 0 0 0 0 0.007
(0.081)
Non-eye related, mean (SD)
General practitionera 1.346 (1.909) 1.427
(2.446)
1.356 (2.039) 1.405
(2.097)
1.070 (1.550) 1.196
(2.081)
1.174 (1.711) 1.296
(2.004)
1.150 (2.122) 1.079
(1.814)
1.182 (2.060) 1.073
(1.725)
0.979 (1.664) 1.132
(1.924)
General practitioner
nurse
0.415 (0.999) 0.394
(1.046)
0.439 (1.023) 0.480
(1.096)
0.316 (0.666) 0.549
(1.371)
0.424 (0.840) 0.529
(1.211)
0.406 (1.374) 0.365
(0.811)
0.435 (1.003) 0.356
(0.827)
0.378 (0.786) 0.493
(0.991)
Social worker 0.006 (0.075) 0.011
(0.106)
0.009 (0.096) 0.003
(0.055)
0.003 (0.056) 0.010
(0.126)
0 0.003
(0.058)
0.017 (0.174) 0.026
(0.354)
0.007 (0.083) 0.003
(0.059)
0.024 (0.266) 0.003
(0.058)
Home care worker 0 0.008
(0.092)
0.003 (0.056) 0.006
(0.078)
0.044 (0.733) 0.010
(0.126)
0.068 (1.16) 0 0.010 (0.175) 0 0.007 (0.083) 0 0.003 (0.058) 0
Other community
services
0.073 (0.705) 0.025
(0.231)
0.157 (1.269) 0.142
(1.093)
0.039 (0.312) 0.089
(1.168)
0.084 (1.024) 0.127
(1.113)
0.032 (0.243) 0.010
(0.101)
0.101 (0.860) 0.042
(0.311)
0.048 (0.421) 0.154
(1.473)
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Baseline 6 months 12 months 18 months 24 months 30 months 36 months
Medicine-1st
(n= 362)
Laser-1st
(n= 356)
Medicine-1st
(n= 326)
Laser-1st
(n= 329)
Medicine-1st
(n= 317)
Laser-1st
(n= 317)
Medicine-1st
(n= 302)
Laser-1st
(n= 302) Medicine-1st Laser-1st Medicine-1st Laser-1st Medicine-1st Laser-1st
Acute hospital servicesb
Outpatient,
mean (SD)
0.838 (1.331) 0.707
(1.259)
0.808 (1.826) 0.911
(1.948)
0.551 (1.350) 0.543
(1.230)
0.620 (1.489) 0.568
(1.283)
0.562 (1.193) 0.685
(1.602)
0.553 (1.431) 0.582
(1.491)
0.642 (1.378) 0.5
(1.092)
A&E attendance,
mean (SD)
0.062 (0.252) 0.085
(0.343)
0.049 (0.256) 0.085
(0.447)
0.061 (0.299) 0.098
(0.472)
0.077 (0.313) 0.06
(0.370)
0.048 (0.244) 0.093
(0.641)
0.075 (0.381) 0.070
(0.294)
0.083 (0.416) 0.067
(0.288)
Day case, mean (SD) 0.352 (0.839) 0.316
(0.828)
0.297 (1.091) 0.287
(0.826)
0.244 (0.690) 0.220
(0.688)
0.306 (0.950) 0.194
(0.584)
0.199 (0.771) 0.276
(0.837)
0.264 (0.890) 0.345
(1.275)
0.315 (1.022) 0.248
(0.759)
Planned inpatient
admission, n (%)
11 (3) 6 (2) 6 (2) 8 (2) 5 (2) 8 (3) 10 (3) 10 (3) 2 (1) 8 (3) 6 (2) 8 (3) 5 (2) 5 (2)
LOS planned
inpatient admissions,
mean (SD)c
1.091 (0.302) 1 (0) 1.333 (0.516) 1.125
(0.354)
1 (0) 1.125
(0.354)
1.1 (0.316) 1.1
(0.316)
1 (0) 1.125
(0.354)
1.667 (0.516) 1.5
(1.414)
1.4 (0.548) 1 (0)
Emergency inpatient
admission, n (%)
5 (1) 3 (1) 5 (2) 9 (3) 8 (3) 10 (3) 9 (3) 8 (3) 3 (1) 5 (2) 8 (3) 11 (4) 10 (3) 6 (2)
LOS emergency
inpatient admissions,
mean (SD)c
1.2 (0.447) 1 (0) 1 (0) 1.889
(2.315)
1.25 (0.463) 1 (0) 1 (0) 1.125
(0.354)
1 (0) 1 (0) 1 (0) 1.545
(0.688)
1.7 (1.337) 1.5
(1.224)
A&E, accident and emergency; LOS, length of stay.
a Visit, telephone call, home visit.
b Excluding ophthalmology.
c For LOS, mean and SD is reported for patients with an admission only.
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